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Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown etiology with no effective 
treatment except for lung transplantation. It is characterized by progressive lung fibrosis leading 
to respiratory failure. Outcomes are worse with comorbidities such as right ventricular systolic 
dysfunction (RVSD) and pulmonary hypertension (PH). Consequently, there is an urgent need 
for novel treatment approaches for IPF. This dissertation aims to (1) determine the strength of the 
association between hemodynamic indices of right ventricular function and survival in IPF, (2) 
evaluate the therapeutic potential of human bone-marrow derived mesenchymal stem cells 
(hMSCs) and their derived exosomes in regulating the right ventricular function in a mouse 
model of IPF, and (3) categorize the protein cargo of hMSCs. 
The analysis of the data from an IPF registry showed that the risk of death was 
significantly higher among subjects with PH in IPF compared to IPF alone (HR: 1.406; 95% CI: 
1.026-1.928). Similarly, the risk of mortality was significantly higher in subjects with RVSD 
compared to those without (HR: 2.523; 95% CI: 1.599-3.979). We concluded that PH and RVSD 
were strongly associated with survival and that right heart catheterization hemodynamic 
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assessments in IPF is crucial to identify patients at risk of worse outcomes who may be 
considered for clinical trials. 
In evaluating the potential beneficial effects of hMSC and their exosomes in fibrotic lung 
injuries, we found that the mean pulmonary arterial pressure was significantly increased in the 
BLM group when compared with controls (20.0±0.45 vs 16.1±0.43, mmHg). Also, there was a 
significant increase in right ventricular dysfunction (dP/dtmx-EDV) when comparing the BLM 
group with controls (45.5±2.52 vs 32.8±2.87, mmHg.s-1. ul-1) with an improvement in the RVD 
after administering hMSCs and exosomes. We concluded that hMSCs and their exosomes have 
the therapeutic potential to regulate the RV contractile function.  
Lastly, we performed a descriptive proteomic analysis to identify and categorize the 
protein components of the hMSC exosomes. We identified 845 proteins, 166 of them had 
enzymatic activities involved in proteolysis and oxidative stress regulation. Our conclusion was 
that the proteome of hMSC exosomes carry enzymatic proteins that could mediate their 
therapeutic effects.  
 vi 
TABLE OF CONTENTS 
PREFACE .................................................................................................................................. XII 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 EPIDEMIOLOGY OF IPF .................................................................................... 1 
1.2 AIMS AND RATIONALE .................................................................................... 1 
1.3 COMORBIDITIES ASSOCIATED WITH SURVIVAL IN IPF ......................... 2 
1.3.1 Pulmonary hypertension in IPF ......................................................................... 4 
1.3.2 RVD in IPF ........................................................................................................ 5 
1.4 MOUSE MODEL OF IPF ..................................................................................... 5 
1.5 THE THERAPEUTIC POTENTIAL OF HMSCS AND THEIR EXOSOMES ... 6 
1.5.1 Human mesenchymal stem cell-released exosomes .......................................... 8 
1.6 RIGHT HEART CATHETERIZATION AND INDICES OF RVD ..................... 9 
1.7 THE POTENTIAL MECHANISTIC PATHWAYS OF HMSC EXOSOMES .. 10 
2.0 HEMODYNAMIC CHARACTERISTICS OF SURVIVAL IN IPF: ANALYSIS 
FROM THE SIMMONS CENTER FOR INTERSTITIAL LUNG DISEASES REGISTRY  
  ...................................................................................................................................... 13 
2.1 INTRODUCTION ............................................................................................... 13 
2.2 METHODS .......................................................................................................... 16 
2.2.1 IPF registry ...................................................................................................... 16 
 vii 
2.2.2 Data collection ................................................................................................. 16 
2.2.3 Sample size and power analysis ...................................................................... 17 
2.2.4 Statistical analysis............................................................................................ 18 
2.2.5 Primary endpoint ............................................................................................. 19 
2.3 RESULTS ............................................................................................................ 19 
2.3.1 Study population .............................................................................................. 19 
2.3.2 Demographics .................................................................................................. 19 
2.3.3 Pulmonary functional tests .............................................................................. 21 
2.3.4 Survival analysis .............................................................................................. 22 
2.3.5 Cox proportional hazard regression analysis. .................................................. 24 
2.3.5.1 Unadjusted analysis............................................................................... 24 
2.3.5.2 Multivariable analysis ........................................................................... 25 
2.4 DISCUSSIONS.................................................................................................... 27 
3.0 THE THERAPEUTIC POTENTIAL OF MSC-DERIVED EXOSOMES IN 
FIBROTIC LUNG INJURY ...................................................................................................... 31 
3.1 INTRODUCTION ............................................................................................... 31 
3.2 MATERIALS AND METHODS ........................................................................ 34 
3.2.1 Design .............................................................................................................. 34 
3.2.2 Isolation and Characterization of human MSC-derived exosomes ................. 34 
3.2.3 Mouse model of bleomycin-induced fibrotic lung injury ................................ 35 
3.2.4 Animal handling and pressure-volume loop measurements ............................ 36 
3.2.5 Pressure-volume loop analysis ........................................................................ 36 
3.2.6 Primary and secondary outcomes .................................................................... 37 
 viii 
3.2.7 Sample size and power calculations ................................................................ 37 
3.2.8 Statistical analysis............................................................................................ 37 
3.3 RESULTS. ........................................................................................................... 38 
3.3.1 Cardiopulmonary hemodynamic data. ............................................................. 39 
3.3.2 Afterload .......................................................................................................... 41 
3.3.3 Contractility ..................................................................................................... 41 
3.3.4 Coupling efficiency ......................................................................................... 43 
3.4 DISCUSSIONS.................................................................................................... 43 
4.0 A DESCCRIPTIVE PROTEOMIC ANALYSIS OF HMSC EXOSOMES: 
THERAPEUTIC IMPLICATIONS IN FIBROTIC LUNG DISEASES ............................... 47 
4.1 INTRODUCTION ............................................................................................... 47 
4.2 MATERIALS AND METHODS ........................................................................ 53 
4.2.1 Design .............................................................................................................. 53 
4.2.2 Source of human MSCs and exosome isolation .............................................. 53 
4.2.3 Pooling and purification of exosomes ............................................................. 53 
4.2.4 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and in-gel 
digestion ....................................................................................................................... 55 
4.2.5 Liquid chromatography tandem mass spectrometry ........................................ 55 
4.2.6 Identification of peptides and proteins ............................................................ 56 
4.2.7 The Kyoto Encyclopedia of Genes and Genomes pathway analysis ............... 57 
4.2.8 Statistical analysis............................................................................................ 57 
4.3 RESULTS ............................................................................................................ 59 
4.4 DISCUSSIONS.................................................................................................... 63 
 ix 
5.0 CONCLUSIONS ........................................................................................................ 68 
6.0 FUTURE DIRECTIONS ........................................................................................... 69 
APPENDIX A .............................................................................................................................. 70 
BIBLIOGRAPHY ....................................................................................................................... 71 
 x 
 LIST OF TABLES 
 
Table 1. Characteristics of IPF patients with IPF alone and PH in IPF ........................................ 20 
Table 2 Characteristics of patients with RVSD and preserved RV function ................................ 21 
Table 3 Cox proportional hazard for overall mortality in RVSD and PH in IPF ......................... 25 
Table 4 Hemodynamic characteristics and indices of pressure-volume relationships ................. 40 
Table 5 A. All 845 identified proteins; B. Main biological processes of the 166 identified 
enzymes......................................................................................................................................... 60 
Table 6 Distribution of enzymes by class in hMSC exosome proteome ...................................... 61 
Table 7  Meaning of acronyms and abbreviations ........................................................................ 70 
 xi 
LIST OF FIGURES 
 
Figure 1 A conceptual framework integrating the three aims....................................................... 12 
Figure 2 Overall survival curve with a decline from 1 (365.25) to 5 (1830) years following 
diagnosis ....................................................................................................................................... 22 
Figure 3 KM survival estimates. (A) PH in IPF vs IPF alone (B) RVSD vs preserved RV 
function ......................................................................................................................................... 23 
Figure 4 Correlation plot of mPAP vs SVI ................................................................................... 26 
Figure 5 Dot plots: Indices of RV contractility (A & B), afterload (C) and coupling efficiency 
(D). ................................................................................................................................................ 39 
Figure 6 Slopes of the end-systolic pressure-volume relationships .............................................. 42 
Figure 7 .  hMSC exosome size distribution profile; mean size (90nm) ...................................... 54 
Figure 8 Distribution of enzymes by class in hMSC exosome proteome with their protein 
symbols ......................................................................................................................................... 62 
 xii 
PREFACE 
This PhD dissertation is dedicated to my beloved late sister, Lucy Eni Munakwa, who passed 
away from a malignant tumor in September 2016. Sister, you inspired me to keep fighting even 
when the odds are not in our favor.  
This has been a long academic journey with many bumps along the way and encountering 
many wonderful people who have lifted me up and encouraged me to forge ahead. I will like to 
start by thanking my Almighty Creator for giving me the good health and strength to tackle this 
challenging but rewarding endeavor. This work would not have been possible without the 
constructive comments, suggestions and insightful inputs from my committee members that have 
advanced my knowledge and skills in generating a scientific article. I want to specially recognize 
and thank my mentor Dr. Luis Ortiz who introduced me into the field of basic biomedical 
research and provided the platform to conduct this work. Your human touch to our personal 
relationship has been a blessing to my personal growth as a person and a scientist. To Dr. Galen 
Switzer, my academic advisor, for his continuous guidance and encouragement from the first day 
I met him as a new PhD student. 
This work certainly would have been difficult to accomplish without the assistance of Mr. 
Elan Cohen at the University of Pittsburgh Data Center for his assistance in cleaning and coding 
part of the data for statistical analysis. Dr. George Leikauf and Dr. James Fabisiak for their 
assistance and guidance with the proteomic and KEGG pathway analysis. Dr. Berthony 
 xiii 
Deslouches and Dr. Kiflai Bein for generously proofreading this work. To my laboratory 
colleagues, present and past, Dr. Michelangelo DiGiuseppe, Brian Brockway, Dr. Antonella 
Marrocco and Ariana Detwiler for their assistance and friendly support on numerous occasions 
over the years. I will like to acknowledge the personnel at the Vascular Medicine Institute and 
Biomedical Mass Spectrometry Center at the University of Pittsburgh for conducting the 
pressure-volume loop and proteomic analysis, respectively. 
Finally, I will forever be grateful to my loving and caring wife, Vivian, and our three 
wonderful kids, Marielle, Belisse and Joevi for their continued love and tireless support despite 
my never-ending quest for knowledge. To my dear sisters and their amazing husbands, Mrs. 
Grace Tekum and Mrs. Mercy Tebit, words cannot describe the impact of your unwavering 
affection and prayers on my drive to succeed. I thank you all immensely. 
 
 
 
 1 
1.0  INTRODUCTION 
1.1 EPIDEMIOLOGY OF IPF 
Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal disease of unknown etiology with 
no effective cure except for lung transplantation. It is characterized by progressive lung fibrosis 
leading to difficulties in breathing and a short median survival of 3-5 years 1. The estimated 
prevalence of IPF in the United States is between 28 to 63 cases per 100,000 persons with about 
50,000 annual incident cases 2, 3. Despite the unpredictable course of IPF, outcomes are worse 
with an associated right ventricular (RV) dysfunction (RVD) and pulmonary hypertension (PH) 4, 
5.Consequently, there is an urgent need for novel treatment options for IPF and its comorbidities. 
1.2 AIMS AND RATIONALE 
In this dissertation we tried to achieve three aims in three independent projects. Our first aim was 
to determine the strength of the association between hemodynamic indices of RVD and survival 
based on data from an IPF registry. For a rare disease such as IPF with a short median survival, a 
registry with structured data entry spanning several years will be a good resource to gather 
sufficient data to address this question. We hypothesized that patients with PH in IPF will have 
increased rates of RVD and poorer survival. In the second aim, we sought to evaluate the role of 
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hMSC and their derived exosomes in modulating the RV function in an experimental animal 
model of fibrotic lung injury. There is accumulating evidence on the beneficial effects of bone 
marrow-derived human mesenchymal stem cells and their secreted exosomes in fibrotic lung 
diseases and RV function 6-8. A greater impetus is therefore needed to rapidly translate this 
promising novel therapeutic strategy into clinical applications. In view of this, we sought in our 
second aim to evaluate the role of hMSC and their derived exosomes in modulating the RV 
function in an experimental animal model of fibrotic lung injury. We hypothesized that hMSCs 
exosomes exert their beneficial effects in part, by modulating RV contractility. Lastly, in our 
third aim, we sought to identify and categorize the protein components of hMSC exosomes by a 
qualitative proteomic analysis. We questioned if the observed beneficial effects of hMSC 
exosomes could be partly explained by the composition of their protein cargo. These three aims 
are conceptualized in the conceptual framework below. The biogenesis of EVs is key to 
understanding the subcellular origins of extracellular vesicles that may in part, explain the 
differences in the protein cargo of microvesicles, budding from the plasma membrane and 
exosomes that originate from mature intracellular endosomal multivesicular bodies. 
1.3 COMORBIDITIES ASSOCIATED WITH SURVIVAL IN IPF 
The correlation between RVD and survival has been widely reported based on studies conducted 
in patients with idiopathic pulmonary arterial hypertension (IPAH) 9, 10. Nonetheless, there is a 
critical difference in the definition of IPAH and pulmonary hypertension in IPF (PH in IPF). 
Therefore, motivated by the need to highlight these differences and harmonize the diagnosis and 
treatment of PH, a series of world symposia were held under the sponsorship of the World 
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Health Organization since 1973 to the latest in 2013 11, 12. The robust discussions during these 
symposia led to a clear definition and classification of PH. Consequently, PH in general, is 
defined as a hemodynamic and pathophysiological condition with an increase in mean 
pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, assessed by right heart catheterization 
(RHC). Idiopathic pulmonary hypertension was classified as a group 1 PH, which is 
characterized by the presence of pre-capillary PH in the absence of other causes of pre-capillary 
PH. PH in IPF was classified as a group 3 precapillary PH due to lung diseases or hypoxia. To 
differentiate PH in IPF from the group 2 postcapillary PH due to left-sided heart disease, a 
second hemodynamic parameter in the diagnosis of PH in lung diseases was introduced. This 
was a pulmonary capillary wedge pressure (PCWP) ≤15 mmHg 12. Several studies comparing 
hemodynamic parameters and survival of patients with precapillary PH (group 1, IPAH and 
group 3, PH in IPF), suggest a direct correlation between pulmonary hypertension and poor 
survival 13-15. Put together, these studies suggest that treating PH alone may prolong survival in 
IPF. Nonetheless, the updated American Thoracic Society (ATS)/European Respiratory Society 
(ERS) clinical practice guidelines of 2015, maintained the 2011 guidelines against treating PH in 
IPF 16. They argued that the current vasoactive therapies for IPAH are more likely to worsen the 
already compromised gas exchange in IPF patients. Pulmonary functional tests (PFTs) are often 
conducted to assess disease progression based on lung volumes with forced vital capacity percent 
predicted (%FVC) and gas exchange with diffusion capacity for carbon monoxide percent 
predicted (%DLco) 17. Clinically significant reductions in FVC and DLco that correlate with 
increased mortality have been shown to be greater than 10% and 15%, respectively 18. Recently, 
Paterniti M. et al, studying the PFTs of placebo subjects in  the nintedanib-INPULSIS 1/2 and 
pirfenidone-CAPACITY 004/006, ASCEND clinical trials, found that subjects with less than 
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55% and 36% of %FVC and %DLco, respectively, had the highest risk of death 19. Collectively, 
the results from these clinical trials led to the approval of pirfenidone and nintedanib in the 
treatment of IPF, based on reductions in the decline of the % predicted FVC but with little or no 
improvements in mortality 19. Therefore, other factors that correlate strongly with mortality are 
needed for optimal patient management. 
1.3.1 Pulmonary hypertension in IPF 
Patients suffering from IPAH are reported to be dying mostly from the failing right ventricle 20. 
Until recently, the right ventricle was considered a bystander conduit for blood to the lungs but 
advances in studying PH have generated interest in understanding its adaptative role in 
pulmonary pressure overloads 21. Therefore, based on the accumulating evidence on the 
importance of the right ventricle in PH, the NHLBI working group on the molecular and cellular 
mechanisms of RV failure, published a 2006 report emphasizing the need to assess the RV 
function in relation to cardiopulmonary diseases, including PH in IPF 20. Consequently, Vonk 
Noordegraaf and others have proposed a progressive adaptation of the right ventricle, from RV 
hypertrophy (to maintain RV to pulmonary arterial coupling) to RV dilatation that results in 
uncoupling or overt RV failure 10, 22. These adaptational steps are reported to begin with an 
increased RV contractility and myocardial hypertrophy, followed by progressive contractile 
dysfunction due to maladaptive RV dilation 4, 23, 24. The failing RV is therefore, characterized by 
an initial increase in contractility followed by a progressive weakening in contractility as the RV 
afterload overcomes contractility 25, 26. Validated indicators of RVD are therefore, essential in 
assessing the transition from adaptive (increased RV contractility) to maladaptive (RV dilatation) 
RVD and in determining how they correlate with survival in IPF. 
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1.3.2 RVD in IPF 
Different hemodynamic indices of RVD and PH have been shown to have various prognostic 
values and strength of association with survival. Wauthy and associates, investigating RV-
pulmonary arterial uncoupling (failing RV) in large animal models, demonstrated that survival 
was strongly associated with RV systolic dysfunction (RVSD) than with elevated pulmonary 
artery pressures 27. These authors defined uncoupling as the inability of the RV to maintain a 
normal stroke volume with increased pulmonary pressure overload. This report indicates indices 
of RVSD might have better prognostic values than pulmonary pressures when appropriate 
modalities are used for its assessment.  
1.4 MOUSE MODEL OF IPF 
Currently, there is no effective treatment for IPF and the recently approved pirfenidone and 
nintedanib, at a prohibitive cost only help in slowing IPF progression. It is therefore, imperative 
to translate evidence-based findings from preclinical animal models into clinical applications that 
have the potential to treat IPF and improve survival. Animal models of IPF and its comorbidities 
are crucial in studying the pathogenesis of IPF and their response to treatment. Mouse bleomycin 
(BLM) pulmonary fibrosis model is an established model that has been useful in elucidating 
major aspects of our current knowledge on IPF. Bleomycin is a glycopeptide antibiotic produced 
from the bacteria, Streptomyces verticillus. It has traditionally been used as a cytotoxic agent in 
cancer chemotherapy based on its properties of inducing oxidative DNA breakage 28, 29. The 
initial histopathological lung injury associated with BLM, recapitulates human IPF with either 
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peribronchiolar or subpleural basal lesions depending on whether it was administered 
intratracheally or subcutaneously, respectively 30. BLM-induced fibrotic lung injury (BFLI) in 
rodent models has been shown to be associated with pulmonary hypertension (PH)30. Therefore, 
as in human IPF where the outcome is often complicated by right ventricular (RV) dysfunction 
(RVD) and PH 5, 15 , these comorbidities are likely to be present in animal models of BFLI. 
Using a mouse model of BFLI, Hemnes A et al, reported an improvement in pulmonary vascular 
remodeling and RV hypertrophy after administering sildenafil, a selective phosphodiesterase 
type 5 (PDE5) inhibitor 30. This study and others confirmed the use of the mouse BLM-induced 
model as an ideal model to study the beneficial effects of hMSCs in BFLI 31.  
1.5 THE THERAPEUTIC POTENTIAL OF HMSCS AND THEIR EXOSOMES  
Mesenchymal stem/stromal cells (MSCs) are multipotent cells that have the capacity for self-
renewal and differentiation into multiple lineages, including adipocytes, chondrocytes, and 
osteocytes 32. They were first discovered by Friedenstein and colleagues in the late 1960s as cells 
from the bone marrow which adhere to plastic with a fibroblastoid shape 33, 34. Since then, there 
has been a dramatic increase in the number of published articles on the therapeutic potential of 
hMSCs in different disease conditions, particularly in pulmonary fibrosis 35, 36. Though most of 
the over 10,000 reports from preclinical trials on their beneficial effects have been on bone 
marrow-derived MSCs, these cells have now been isolated from nearly every tissue, including 
fat, umbilical cord, placenta and embryonic stem cells 33, 37, 38. An updated review by Squillaro et 
al showed that since June 2015, there were 493 reported MSC-based clinical trials. Of these, 23 
(4.8%) involved lung diseases and 73 (14.8%) cardiovascular diseases 39. Unfortunately, these 
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published reports had major discrepancies in the definition and characterization of MSCs, 
prompting the International Society for Cellular Therapy (ISCT) in 2006, to propose minimal 
criteria for defining hMSCs: hMSCs must be plastic-adherent in culture; positive for CD105, 
CD90, CD73; negative for CD45, CD34, CD11b, HLA-DR surface markers and lastly, must 
differentiate into osteoblasts, adipocytes and chondroblasts 32. These minimal standards have led 
to improvements in the consistencies in the methods used to isolate and expand MSCs. 
Nonetheless, there is still the need for biomarkers that can quantitatively delineate high quality, 
therapeutic potent MSCs 40, 41. Recent animal studies have shown a correlation between the 
therapeutic potential of allogeneic hMSCs with the dose and timing of their transplantation 33, 42. 
Most of these studies have confirmed the efficacy of MSCs early during the inflammation phase 
and not after established FLI 33, 43. Unfortunately, due to the insidious nature of the onset of IPF, 
most patients present late in hospitals with established progressive lung fibrosis, thus questioning 
the translation potential of the observed pre-clinal benefits, during the acute inflammatory phase, 
to clinical trials on patients with established chronic lung fibrosis. Furthermore, the efficacy of 
these cells is also associated to the lack of homogeneity of the transplanted hMSCs. The 
heterogeneity of MSC populations during isolation and their expansion in culture has raised 
concerns among investigators because of the likelihood of variations in their therapeutic potency. 
Therefore, reproducible, standardized protocols for the isolation and expansion of clonal MSCs 
in culture are needed to produce homogeneous cell populations with predictable potency 43. To 
this end, biomarkers to predict the potency of MSCs from different donors will be necessary to 
translate their ameliorating effects from preclinical animal models into clinical applications 40, 41. 
However, the role of endogenous stem cells/progenitor cells in tissue repair and how they 
interact with exogenous injected MSCs is still not fully understood 33, 44. It will be crucial to 
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delineate the relative contributions of exogenous from endogenous stem cells in FLI repairs. 
Even though the mode of actions of MSCs remain poorly understood, the paracrine concept as a 
mechanism employed by MSCs to impart their beneficial effects is increasingly recognized, in 
part by their release of EVs 33, 45, 46. 
1.5.1 Human mesenchymal stem cell-released exosomes 
Mesenchymal stem cells release membrane-bound vesicles that encompass exosomes and 
microvesicles (MVs). Exosomes (30-100nm) originate from mature endosomal multi-vesicular 
bodies, while the larger MVs (0.1-1um) are formed by outward budding off the plasma 
membrane 47, 48. Recent studies have shown that these EVs carry cytoplasmic nucleic acids 
(mRNA, microRNA), membrane proteins and lipids that are specific to the parent cell type and 
are mediators of the change in differentiation state of recipient cells or their reprogramming 45, 49. 
Specifically, exosomes have been demonstrated to be enriched in microRNAs (miRs) and 
mRNAs, while MVs have little or no RNA, suggesting exosomes because of their endosomal 
origins might be better effectors of the beneficial MSC effects 46, 50. Other studies suggest a 
synergistic mode of action of these EVs to exert pleiotropic beneficial effects in tissue repair 45, 
especially in modulating the RV function. Therefore, innovative techniques will be needed to 
accurately evaluate the adaptive changes in the RV function as a result of the increasing 
pulmonary pressure overload and their response to hMSC exosomes treatment. 
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1.6 RIGHT HEART CATHETERIZATION AND INDICES OF RVD  
Right heart catheterization (RHC) and PV loop analysis remain the gold standard for defining 
changes in PH and assessing the hemodynamic load on the RV 4. Recent studies indicate the 
changes in RV function begin prior to the setting in of overt PH 26, 51. Furthermore, growing 
evidence suggest the RV adapts to increased afterload by increasing its wall thickness 
(hypertrophy) and contractility 4, 24. When these adaptive compensatory mechanisms are 
overwhelmed by the increasing pulmonary pressure overload, RVD ensues and progressively 
lead to uncoupling of the RV from the pulmonary vasculature. Uncoupling has been defined as 
‘the inability of the RV to maintain a normal stroke volume with increasing pressure overload’. 
Wauthy and associates investigating RV-pulmonary arterial uncoupling in large animal models, 
found that worse survival was strongly associated to RV systolic dysfunction (RVSD) and not to 
the elevated pulmonary artery pressures 27. Unlike PH with well validated and standardized 
indices for its assessment, there are no well standardized indices for assessing RVD. In an 
attempt to address the lack of standardized indictors for RVD, experts at  the Fifth World 
Symposium on Pulmonary Hypertension held in 2013, adopted a definition of RV failure 
secondary to PH as, “a complex clinical syndrome due to a suboptimal delivery of blood or 
elevated systemic venous pressure at rest or exercise as a consequence of elevated RV afterload” 
11.  
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1.7 THE POTENTIAL MECHANISTIC PATHWAYS OF HMSC EXOSOMES 
There is accumulating evidence on the beneficial effects of hMSCs in a wide range of diseases, 
including fibrotic lung diseases and their induced pulmonary hypertension and right ventricular 
dysfunction. However, the underlying mechanisms by which hMSCs impart their beneficial 
effects are still actively being investigated. The fact that few MSCs engraft at the site of injury 
led to a shift in the concept of the potential pathways used in their ameliorating effects; from 
engraftment and differentiation, to replace damaged resident cell types, to the release of 
paracrine effectors 33, 52. Insoluble extracellular vesicles are a major part of the hMSC paracrine 
secretome.  
Mesenchymal stem cells release membrane-bound EVs that encompass exosomes and 
microvesicles (MVs). Exosomes (30-100nm in diameter) originate from mature endosomal 
multi-vesicular bodies, while the larger MVs (0.1-1um in diameter) are formed from plasma 
membrane blebs 48, 53. Recent studies have shown that these EVs carry cytoplasmic nucleic acids 
(mRNA, microRNA), membrane lipids and proteins that are specific to their parent cell type and 
are potential mediators of changes in the differentiation state of recipient cells 45, 49. Specifically, 
exosomes have been demonstrated to be differentially enriched in microRNAs (miRs), while 
MVs have little or no miRs, suggesting exosomes may be better mediators of the beneficial MSC 
effects 46, 50. Other reports suggest a synergistic mode of action of these EV subtypes to optimize 
their pleiotropic beneficial effects in tissue repair 45.  
Recently, we showed that MSCs exert their beneficial actions in part, by shuttling miRs 
and proteins loaded in EVs to target cells leading to a change in their bioenergetic phenotype 45. 
Other investigators have shown that hMSC exosomes contribute to the ameliorating effects in 
myocardial infarction 54, pulmonary hypertension 55, 56, and pulmonary fibrosis 6, 37. Collectively, 
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these studies suggest a potential cross-talk between hMSC exosomes and target cells, such as 
endothelial cells, cardiomyocytes, and lung epithelial cells for tissue repair. A greater 
understanding of the molecular and cellular pathways in the pathogenesis of RV and pulmonary 
artery remodeling in fibrotic lung diseases will help in the development of novel therapeutic 
strategies. To this end, some investigators have proposed mechanistic pathways that involve the 
generation of excessive reactive oxygen species (ROS) as crucial in the pathogenesis of fibrotic 
lung disease 57 and right ventricular hypertrophy 58. Furthermore, others have postulated an 
increased expression of NADPH oxidase (NOX) and mitochondrial ROS production as key 
sources of ROS that correlate with progressive RV hypertrophy 59-61. These data suggest a 
deleterious effect of oxidative stress on the normal function of the right ventricle and pulmonary 
vasculature that has triggered interest in the development of mitochondria-based therapy, such as 
MitoQ, to treat cardiac hypertrophy 62. Importantly, oxidative stress is directly associated with an 
increase in misfolded proteins 63, which are toxic to cells as reported in a wide range of 
neurogenerative and age-related diseases such as IPF. The ATP-dependent proteolytic, 26S 
ubiquitin/proteasome system is crucial in recognizing and selectively degrading misfolded 
proteins 64, 65. Proteolytic enzymes are therefore needed to clear these misfolded intracellular and 
extracellular proteins. Proteasomes are an essential group of hydrolase proteolytic enzymes that 
have been found in hMSC exosomes. According to Lai et al, proteasomes played an important 
role in the clearing of misfolded proteins to mitigate ischemia/ reperfusion (I/R) injury 66. Taken 
together, these data indicate a pivotal role of proteasomes in the clearance of misfolded proteins 
with a potential proteolytic role in the extracellular matrix (ECM). Their proteolytic actions may 
have a synergistic effect with matrix metalloproteinases (MMP). The gelatinases (MMP2 and 
MMP9) are MMPs that have been shown to play an important role in ECM turnover and have 
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also been identified in MSC exosomes 67. However, despite our current understanding of the role 
of antioxidant and proteolytic enzymes in health and disease, the hMSC exosome proteome has 
not been investigated to specifically identify these potential paracrine effectors.  
 
 
Figure 1 A conceptual framework integrating the three aims 
. 
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2.0  HEMODYNAMIC CHARACTERISTICS OF SURVIVAL IN IPF: ANALYSIS FROM 
THE SIMMONS CENTER FOR INTERSTITIAL LUNG DISEASES REGISTRY  
2.1 INTRODUCTION 
Right ventricular dysfunction has been shown to directly correlate with worse survival in group 1 
IPAH4, 9. Most of the studies on IPAH used doppler echocardiography to assess the RV function. 
Though noninvasive and suitable for follow-up assessments of patients, echocardiographic 
techniques have shown limited accuracy in measuring RV function in advanced lung diseases5, 
15. Some reports have shown accuracy as low as 40% when compared with RHC measurements 
68. Furthermore, echocardiograms have the disadvantage that the parameters they measure are 
load-dependent and lack the ability to study the intrinsic properties of the right heart69. 
Notwithstanding, echocardiography has provided added insight into the adaptive changes in 
shape and size during right heart filling and output.  
 In 2013, Rivera-Lebron and colleagues used echocardiographic parameters, including 
tricuspid annular plane systolic excursion (TAPSE) as a measure of RV ejection fraction and RV 
outflow tract velocity-time integral (RVOT VTI) as a surrogate for stroke volume. They found 
that those with RVD in IPF had significantly lower TAPSE (1.8 cm vs 2.1 cm; P=0.01) 15. 
Similarly, D’Andrea et al, used another echocardiographic technique, speckle-tracking (2D 
strain) echocardiography (2D STE) to quantify RV regional deformation and RV contractile 
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impairment in 55 IPF patients. They found a significant reduction in global longitudinal strain of 
IPF patients when compared with controls ( −18.4 ± 6.1 vs −14.5 ± 6.3) 5. Furthermore, Ghio et 
al, studying 658 consecutive patients with congestive heart failure, showed that a TAPSE ≤14 
mm was more significantly associated with mortality than elevated pulmonary systolic pressure 
with preserved TAPSE. Put together, these echocardiographic studies reinforce the importance of 
TAPSE, a measure of RVD, as a strong prognosticator of survival. However, as earlier 
mentioned, echocardiography is fraught by limitations of delineating the endocardium for 
accurate evaluations of right-sided heart volumes. Thus, the need for invasive RHC and PV loop 
analysis (RHC-PV loop analysis).  
Though minimally invasive, RHC-PV loop analysis is the gold standard for assessing the 
hemodynamic functions of the right heart 51. PV loop analysis have become an essential tool in 
assessing disease progression and adaptation of the RV to the PH-induced increased RV 
afterload 22. It is therefore, imperative to employ RHC to comprehensively study the 
pathophysiology of the failing RV and pulmonary vasculature and determine their association 
with survival However, there are currently no well-established indices for assessing RVD in IPF. 
PV loops generate end-systolic PV relationship slopes (Ees) that have been demonstrated to be 
load-independent 70. Load-independent indices are crucial in assessing the intrinsic RV function 
void of the influence of load and heart rate 71. Also, the interaction of the RV pump and 
pulmonary vascular load, RV-to-pulmonary arterial (PA) coupling, provides a comprehensive 
evaluation of the right ventricle and pulmonary circulation as a functional unit. PV loop analysis 
also, enable assessment of the RV contractility, especially with the evidence that the RV pump 
muscle shortening (contractility) and mass (hypertrophy) are essential elements that contribute to 
optimal RV function 21. However, assessing the RV function in class 3 IPF-associated PH is 
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limited by the lack of well-established indices 72. Recently, Rivera-Lebron and colleagues 
employed transthoracic echocardiography with stroke volume index (SVI) ≤29ml/m² as the 
cutoff for assessing RVD in IPF patients with associated PH 15. More than a decade ago, van 
Wolferen and colleagues reported on the use of right ventricular systolic dysfunction (defined as 
low stroke volumes (≤25ml/m²) in predicting mortality in subjects with pulmonary arterial 
hypertension 9.Therefore, based on these reports we used a threshold level of (SVI≤25ml/m²) to 
assess the RV function in our IPF cohort. 
In this regard, an IPF registry will be an important resource for large epidemiological 
data on real-world characteristics and clinical management of IPF patients 73-75. In a recent 
publication from the Australian IPF registry evaluating baseline characteristics of IPF patients, 
forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLco), 
composite physiological index (CPI) and GAP (gender, age, physiology) were found to be strong 
predictors of mortality 74. Similarly, in a report from the INSIGHTS-IPF registry from Germany, 
the mean FVC was 72±20% predicted and DLco was 35±15% predicted 75. Other regional or 
statewide registries such as the Swedish IPF-Registry have showed that the quality of life of IPF 
patients and their perception of the disease were quite poor 76. Collectively, these studies indicate 
IPF registries are an important source for data on the natural history of the disease, quality of life 
and clinical management of patients. 
Consequently, using hemodynamic data from the Simmons Center for interstitial lung 
diseases (ILDs) registry, we sought to use PV loop analysis to assess RV function and determine 
the strength of their association with survival in IPF patients. We hypothesized that IPF subjects 
with RVD will have worse survival when compared with those with PH in IPF and IPF alone.  
 16 
2.2 METHODS 
2.2.1 IPF registry 
The Simmons Center for interstitial lung diseases (ILDs) registry at the University of Pittsburgh, 
was launched in October 2003 to document medical information from previously and newly 
diagnosed patients with ILDs, including IPF (ClinicalTrials.gov identifier #: NCT00258583). 
The center currently follows over 1400 patients with interstitial lung diseases, most with IPF. 
The center provides comprehensive state-of-the-art care for patients with interstitial lung 
diseases, opportunities for research on lung inflammation and fibrosis, and promotes the 
translation of scientific discoveries into novel therapies, such as stem cells and their derivatives. 
In 2008, the Simmons Center ILDs registry became a member of the Daniel and Joan Beren 
Pennsylvania-statewide IPF (PA-IPF) registry. The PA-IPF registry comprise five participating 
centers that include the University of Pittsburgh, University of Pennsylvania, Temple University, 
Penn State Hershey Medical Center, and Geisinger Health System. The data for this study came 
solely from the Simons Center registry, including doppler echocardiographic, demographic, 
pulmonary functional tests (PFTs) and right heart catheterization (RHC). Patients were 
determined to have IPF according to the 2002 ATS/ERS guidelines 77. These guidelines were 
later revised in 2011 1 and 2015 16. 
2.2.2 Data collection 
Approval for the study (Protocol 13080573) was obtained from the University of Pittsburgh 
Institutional Review Board. The registry was reviewed for patients diagnosed with IPF from 
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between June 1996 to June 2015 to collate deidentified demographic and hemodynamic data into 
electronic spreadsheets. Thereafter, the secondary raw data was cleansed, categorized and 
assigned analytical variable codes with assistance from the University of Pittsburgh Center for 
Research on Health Care Data Center. Patients diagnosed with other diffused interstitial lung 
diseases, who did not meet the 2002 guidelines for IPF were excluded from the study.  
2.2.3 Sample size and power analysis 
The sample size (308) is determined from the number of patients diagnosed with IPF with RHC-
derived hemodynamic data. However, we needed a power analysis to confirm an adequate 
sample size to detect a clinically meaningful difference in the survival probabilities between IPF 
alone and PH in IPF groups. The minimal sample size of 92 for 41 events (deaths) was 
determined to be adequate to detect a 30% difference in mortality between IPF alone and PH in 
IPF subjects. The log-rank test, assuming a chi-square distribution, was used to calculate the 
sample sizes 78 with the “power” command on a STATA software (Stata Corp., College Station; 
version 14.0). Null hypothesis H0: S1(t)=S2(t); Alternative H1: S1(t)≠S2(t); where S1(t)= survival 
probability in the IPF alone group, S2(t)= survival probability in the PH in IPF group. The effect 
size of 30% was consistent with mortality rates reported by Lettieri and colleagues who 
compared the risk of mortality in IPF patients with PH and those without PH 79. The sample size 
was calculated with a power (1-β) of 80%, a type II error (β) of 20% and a significance level of 
less than 0.05.  
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2.2.4 Statistical analysis 
All statistical analyses were performed using a STATA statistical software (Stata Corp., College 
Station; version 14.0). Summary statistics for demographic, pulmonary function tests, and 
hemodynamic characteristics were evaluated. The data were reported as mean ± SEM or as 
median where appropriate and ccategorical variables were summarized as percentages. 
Comparisons of groups were made using unpaired Student t-test, Chi X² or Wilcoxon’s rank-sum 
tests (see Table 1). 
For survival analyses, unadjusted survival functions of dichotomized continuous 
variables of PH in IPF (25< mPAP≥25) and SVI (25≤SVI>25) were estimated using Kaplan-
Meier curves with their log-rank test for statistical significance. Unadjusted and multivariable 
Cox proportional hazard analyses were performed, adjusting for key predictor variables (age, 
gender, heart rates and FVC% predicted). Other clinically meaningful variables were fitted one 
after the other in a model with the above key variables to evaluate the magnitude and 
significance of their association with mortality. A log-log plot was generated to test for the 
proportional hazard assumption. It is worth noting that the test of multicollinearity is inherent in 
the STATA software program. Associations between continuous variables were evaluated using 
Pearson’s correlation test and logistic regressions were performed to evaluate the strength of the 
association between dichotomous variables. The dichotomized predefined threshold values of 
mean pulmonary arterial pressure (mPAP) (≥25 and PCWP ≤15 mmHg) and stroke volume 
index (SVI) (≤25 ml/beat/m²) were evaluated for the presence of pulmonary hypertension or 
right ventricular systolic dysfunction, respectively. The p-value (< 0.05) and their 95% 
confidence intervals (CI) were assessed. for statistical significance. The 95% CI is not assessed 
for significance – it’s additional information. 
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2.2.5 Primary endpoint 
The primary endpoint was overall mortality, assessed by a Cox regression analysis and the 
secondary endpoint was prevalence. Other covariates evaluated were PVR (pulmonary vascular 
resistance), RVSP (right ventricular systolic pressure), and the predicted FVC% (forced vital 
capacity % predicted), FEV1% (forced expiratory volume in one second % predicted), DLco% 
(diffusion capacity for carbon monoxide % predicted) (Table 1). The proportion of missing data 
was small and did not affect our sample size calculations, thus allowing for a complete case 
analysis. Most of the missing data resulted from some subjects missing data points on either 
PFTs or RHC that could not be matched.  
2.3 RESULTS 
2.3.1 Study population 
We identified 880 patients with IPF in the review period from June 1996 to June 2015. Of these, 
308 (35%) had complete hemodynamic and PFTs data. Sixty five percent of the IPF patients that 
were not analyzed had a similar demographic distribution (age, race) with a slight reduction in 
the proportion of males (57% vs 67%) when compared with the analyzed data.  
2.3.2 Demographics 
The overall mean age of the analyzed IPF cohort was 68 years (range 31 to 94) and 67% male. 
The cohort was mostly white, with 836 (95%) followed by African Americans, 18 (2%) and 
others 26 (3%). The PH in IPF subjects comprised mostly older males when compared with IPF 
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only subjects (66 vs 64; p=0.05). The prevalence of PH and RVSD in IPF were 28.6% (88/308) 
and 12.3% (28/228), respectively (Table 1 & 2). 
 
Table 1. Characteristics of IPF patients with IPF alone and PH in IPF 
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2.3.3 Pulmonary functional tests 
There were no significant differences in the mean FVC %  and FEV1% predicted values between 
the PH in IPF and IPF only groups, confirming previous reports that lung volumes do not 
correlate well with patient outcomes 13. The DLCO % predicted was significantly lower in the 
PH in IPF group (30.5 vs 38.7, p= <0.001) (Table 1).  
 
Table 2 Characteristics of patients with RVSD and preserved RV function 
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2.3.4 Survival analysis 
The overall median survival was 3.7 years, and the 1-year and 5-year survival rates were 81.3% 
and 37.5%, respectively (Figure 1).  This showed a rapid decline (43.8%) in survival from one to 
five years after diagnosis. The assumption of constant proportional hazard was determined to be 
satisfactory from a parallel log-log graph. 
 
 
Figure 2 Overall survival curve with a decline from 1 (365.25) to 5 (1830) years following diagnosis 
 
In comparing the Kaplan-Meier survival estimates (Figure 2A), we found a significantly 
lower survival rate among PH in IPF subjects compared with IPF alone. Furthermore, the 
survival estimates were significantly lower in the PH-IPF group at one year (72.3 % vs 85.3%) 
and at five years (37.9% vs 49.6%) than in IPF alone. This suggest a worsening survival outcome 
attributable to PH in IPF. Looking at RV function, the Kaplan-Meier survival estimates of 
subjects with RVSD were significantly lower at one year (67.2% vs 83.7%) and at five years 
(16.8% vs 55.4%) compared to those without RVSD (Figure 2B). Interestingly, these rates were 
5% and 21% lower at one year and five years respectively, among RVSD subjects compared 
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with PH in IPF. This indicate outcomes are markedly worse in IPF patients with associated 
RVSD when compared with PH in IPF. 
 
 
Figure 3 KM survival estimates. (A) PH in IPF vs IPF alone (B) RVSD vs preserved RV function 
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2.3.5 Cox proportional hazard regression analysis. 
2.3.5.1 Unadjusted analysis 
To assess the impact of PH in IPF on survival outcomes, we performed an unadjusted Cox 
regression analysis with a dichotomized mPAP (mean pulmonary artery pressure) as a single 
covariate. The overall risk of mortality (hazard ratio) was significantly higher among subjects 
with PH in IPF compared to IPF alone (HR: 1.406; CI: 1.026-1.928, p= 0.034). More 
importantly, the risk of death was significantly higher in subjects with RVSD compared to those 
without. (HR: 2.523; 95% CI: 1.599-3.979, p= <0.001) (Table 2). Again, RVSD in IPF was 
associated a greater risk of death than PH in IPF. Interestingly, the significant different variables 
(mPAP, RVSP) are indicators of pulmonary vascular load (afterload) related to the 
cardiopulmonary functional unit. 
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Table 3 Cox proportional hazard for overall mortality in RVSD and PH in IPF 
 
 
2.3.5.2 Multivariable analysis 
We adjusted the unadjusted dichotomous mPAP and SVI with key predictor variables age, 
gender, heart rates and FVC% predicted, selected based on literature reports 18. The risk of 
mortality increased and remained significantly higher for PH in IPF subjects compared to IPF 
only subjects (HR: 1.769; 95% CI: 1.229-2.547, p= 0.002). Interestingly, the mortality risk 
remained significantly higher in subjects with RVSD compared to those with preserved RV 
function after adjusting for the key predictors (HR: 1.825; 95% CI: 1.003-3.321, p=0.049) (Table 
3). Consistent with the unadjusted results, RVSD showed a stronger associated with mortality. 
To assess the strength of the association between PH in IPF and RVSD, we performed 
logistic regressions with RVSD as the binary dependent variable and the mPAP as the 
dichotomized predictor variable. The likelihood of having RVSD was 3.38-fold (OR: 3.38; CI: 
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1.44-7.96; p=0.005) higher among those with elevated mPAP (>25mmHg) compared to those 
with normal pulmonary arterial pressures. Therefore, based on these findings, most patients with 
PH in IPF will eventually develop RVSD. 
To determine the association between mPAP and SVI, RVSP, PVR, we performed 
pairwise Pearson’s correlation tests. As expected, the correlation analysis between mPAP and 
SVI, showed a significant but mildly negative associated (r=-0.32, p=<0.001) (Figure 4). This 
indicates a worsening RV function as the mPAP (RV afterload) increases.  
 
 
Figure 4 Correlation plot of mPAP vs SVI 
 
There was also a strong correlation between mPAP and RVSP (r=92; p=<0.001) and 
between mPAP and PVR (r=0.75; p= <0.001). These variables, mPAP, RVSP and PVR are 
highly correlated, suggesting they are factors that measure the same underlying construct of a 
sick cardiopulmonary unit. 
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2.4 DISCUSSIONS 
In this study, we found that the overall median survival was 3.7 years, and the 1-year and 5-year 
survival rates were 81.3% and 37.5%, respectively. There was a 43.8% decline in survival in five 
years following diagnosis. Indicating more than half of the IPF patents died in five years. In 
recent reports, IPF patients have been regrouped as slow (with several years of decline in lung 
function leading to death) and rapid progressors (less than six months of symptoms before their 
first presentation)18. The IPF patients in our cohort appeared to have a spectrum in their 
progression, leaning towards a slow progression pattern. 
The Kaplan-Meier curves showed a significantly lower survival estimates in the PH-IPF 
patients when compared with IPF alone at one year (72.3 % vs 85.3%) and at five years (37.9% 
vs 49.6%). This suggest PH in IPF is associated with worse outcomes. Using RHC, Lettieri and 
colleagues in their evaluation of PH in IPF patients listed for lung transplantation found a one-
year survival of 72% compared to 94.5% in IPF alone. This gives a difference in survival 
between the two groups of 22.5% compared to 13% in our cohort 79. The higher difference in this 
study can be partly explained by the severity of the disease in a cohort made of patients listed for 
lung transplantation with advanced disease. Similarly, looking at patients with advanced lung 
disease awaiting lung transplant, Nathan and colleagues, performed serial RHC for PH in IPF at 
baseline (38.6%) and at the time of lung transplant (86.4%). They found that almost all the IPF 
patients developed PH late in the course of their disease 80. The significant difference between 
these studies and ours is that their IPF cohort came from referral centers where IPF patients are 
listed for lung transplantation, whereas our cohort is from a regional registry that has IPF patients 
with a spectrum of disease severity, which is more indicative of the real-world picture. 
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Conversely, survival estimates of subjects with RVSD were significantly lower at one 
year (67.2% vs 83.7%) and at five years (16.8% vs 55.4%) compared to those without RVSD. 
Interestingly, these rates were lower among RVSD subjects compared with PH in IPF at one-and 
five-year by 5% and 21%, respectively. This indicates outcomes are markedly worse in IPF 
patients with associated RVSD than among those with PH in IPF. 
In the multivariable Cox regression analysis, we found that the risk of mortality remained 
significantly higher for PH in IPF subjects compared to IPF alone (HR: 1.769; 95% CI: 1.229-
2.537) after adjusting for key covariates (age, sex, heart rate and FVC % predicted). 
Interestingly, the mortality risk remained significantly higher in subjects with RVSD compared 
to those with preserved RV function after adjusting for the same key covariates (HR: 1.825; 95% 
CI: 1.003-3.321). More importantly, RVSD showed a stronger association with mortality than 
PH in IPF. There is very limited data with the use of RHC to evaluate the RV function in IPF. 
Nonetheless, Rivera-Lebron et al, studying 135 IPF patients referred for lung transplantation by 
transthoracic doppler echocardiography, found that RVD was associated with doubling of the 
risk of death. The authors used RV outflow tract velocity time integral (RVOT VTI), as a 
surrogate of stroke volume and the right atrial to left atrial ratio to assess RVD. They also 
reported an 11% prevalence of RSD in their cohort of IPF patients evaluated for lung 
transplantation 15.  
Our correlation analyses revealed that the mPAP and SVI, showed a significant but 
mildly negative association (r=-0.32, p=<0.001). Furthermore, there was a strong correlation 
between mPAP and RVSP (r=92; p=<0.001) and between mPAP and PVR (r=75; p= <0.001). 
Interestingly, these variables (mPAP, RVSP, PVR) are all associated with the pulmonary 
vascular load or afterload. Several publications have reported that outcome in PH is more related 
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with the capacity of the RV to adapt to elevated afterload 5, 25. Recently, Corte et al, performed 
RHC on 66 patients with diffuse interstitial lung disease and showed that PVR was an 
independent predictor of mortality (OR, 1.3, P= <0.001) 81. 
Also, the results from this study showed that both PH and RSVD are prevalent in IPF. 
The prevalence of PH in IPF was 28.6%. Lettieri and colleagues reported a 31.6% 79 and Shorr et 
al  reported a 46.1% 82 prevalence of PH in IPF. These prevalence rates may have been 
overestimated since these studies were performed before the 2008 Dana Point conference on 
pulmonary hypertension that set two hemodynamic cutoff points (mPAP≥25mmHg and PCWP 
≤15mmHg at rest by RHC), for the diagnosis of pulmonary hypertension 12. Moreover, these 
studies were conducted in referral centers on the records of IPF patients listed for transplant with 
advanced disease. 
The prevalence of PH in IPF has also been evaluated from registries with a wide range of 
estimates. Lederer and collaborators found that 36% of IPF patients from the US United 
Networks for Organ Sharing (UNOS) database had PH in IPF 83. In a recent publication from the 
UNOS registry, Hayes and colleagues reported a 49% prevalence of PH in IPF following lung 
transplantation 84. Together, these studies indicate that PH in IPF is common and adversely affect 
outcomes. However, none of these studies assessed the impact of the right ventricular function 
on outcomes. 
Our results showed that 12.3% of the IPF patients in our cohort had RVSD. These 
findings are consistent with that of Rivera-Lebron and colleagues who assesses 
echocardiographic predictors of mortality in a cohort of IPF patients referred for lung 
transplantation. They found that in this cohort, the prevalence of moderate to severe RVD was 
 30 
11% and an independent predictor of mortality measured by the ratio of the right atrial to left 
atrial diameter and RVOT VTI  15. 
Limitations. Our study has some limitations, such as the retrospective review from a 
single center registry. Though the data was from a single center, the Simmons Center for ILDs is 
a regional and member of PA-state wide IPF registry with subjects presenting with diverse 
disease severity spectrum and different demographic backgrounds. The diagnosis of IPF is 
ultimately one of exclusion, fact that some of the diagnosis of IPF were made before the 2002 
ATS/ERS criteria for diagnosing IPF. These probably lead to the  misdiagnosis of some IPF 
subjects. Also, the threshold levels in our analysis were predefined based on existing literature 
for both RVSD and PH in IPF. It is, however, possible that different threshold values might have 
yielded different results. We did not include in our analysis the different medications that the IPF 
patients were taking that might affect survival. Notwithstanding these limitations, the strength of 
our study is in the use of data generated by the gold standard RHC, in a registry with real-world 
characteristics to assess the RV function in an IPF-specific population.  
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3.0  THE THERAPEUTIC POTENTIAL OF MSC-DERIVED EXOSOMES IN FIBROTIC 
LUNG INJURY  
3.1 INTRODUCTION 
There is no effective treatment for IPF except for lung transplantation. The recently approved 
antifibrotic/anti-inflammatory medication, pirfenidone and the tyrosine kinase inhibitor, 
nintedanib, only help slow disease progression. Consequently, there is an urgent need for novel 
therapeutic approaches in IPF. It has been argued that IPF is a non-inflammatory condition 
because it is refractory to corticotherapy 1, 85. However, this theory overlooked the role played by 
immune cells in the wound-healing process that has been demonstrated in the pathogenesis of 
IPF86. This suggest that agents with anti-inflammatory properties can be effective therapies in 
IPF. Although the pathogenesis of IPF is not fully elucidated, its histopathologic pattern of usual 
interstitial pneumonia (UIP) is well known. UIP is characterized by areas of 
fibroblast/myofibroblast proliferation, deposition of extracellular matrix (ECM) and collagen, 
referred to as the fibroblastic foci, interspaced with normal lung tissue. This pattern suggests a 
progressive fibroproliferative process 85. Put together, novel therapeutic agents that demonstrate 
pleiotropic anti-inflammatory, antifibrotic and immunomodulatory effects hold promise as 
potential therapeutic options for IPF. There is growing evidence that indicates hMSCs and their 
derived exosomes possess these triple (antifibrotic, anti-inflammatory and immunomodulatory) 
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ameliorating effects in fibrotic lung disease6, 33. More importantly, hMSC exosomes have greater 
appeal as therapy for IPF than their parent MSCs because they are believed to be less toxic with 
a lower risk to immunologic rejection following allogeneic infusions52. Furthermore, hMSC-
derived exosomes have membranes that protect their macromolecular cargo and facilitate their 
storage and scalability. Also, there is a lower risk of inducing changes in chromosome numbers 
(aneuploidy), which is feasible with whole MSC infusions. Interestingly, exosomes are reported 
to have immune-privileged properties just as their parent cells with fewer ethical implications 52, 
53. These posited immune-privilege properties of hMSC exosomes make them prime candidates 
for therapy in fibrotic lung disease-induced RVD. However, there is limited data on the 
modulatory effects of hMSC exosomes on the RV function within the context of FLI-induced 
pulmonary vascular overload. Therefore, it will be biologically relevant to assess the modulatory 
effects of hMSCs and their derived exosomes on the RV function in a mouse model of FLI. 
Right heart catheterization (RHC) and PV loop analysis remain the gold standard for 
defining changes in PH and assessing the hemodynamic load on the RV 4. Nonetheless, it is 
important for PV loop analysis to be performed appropriately by skilled personnel and for the 
results to be reliable and accurate. In unskilled hands, measuring ventricular volumes using PV 
loop analysis can be very challenging. This is because volumes are estimated from the 
conductance of an electric field, generated by miniaturized electrodes in the catheters, which 
passes through blood and the myocardium. To calculate the absolute ventricular volume, the 
contribution of the myocardium to conductance (parallel conductance) has to be removed from 
the total conductance 87. To this end, two catheter-derived PV loop technologies are available; 
the traditional conductance catheter that requires in vivo calibration using a bolus of hypertonic 
saline to estimate the parallel conductance, and the new admittance catheter that instantaneously 
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corrects for the parallel conductance 88. In this study, we used the admittance catheter system 
because of its capability to generate instantaneous absolute volumes without the perilous in vivo 
calibrations linked with the conductance catheters. PV loop analysis with admittance catheters 
have the unique ability to evaluate PH, RV afterload, their interactions and gauge the response of 
the cardiopulmonary unit to novel therapeutics, including hMSC exosomes 4, 24. Importantly, PV 
loop analysis can assess the RV adaptation to the increased RV afterload 26. When these adaptive 
compensatory mechanisms are surmounted by the increasing pulmonary pressure overload, RVD 
ensues and progressively lead to uncoupling (RV failure) of the RV from the pulmonary 
vasculature. To highlight these compensatory changes, Kubba S. et al, reported that RV-PA 
coupling is a preserved when there is an adaptive increase in contractility (onset of RVD) to 
match increased RV afterload 25. This indicates that in compensated RVD, there is RV-PA 
coupling. Uncoupling ensues when RV contractility is not increased to overcome RV afterload, 
which correlates with pulmonary vascular resistance (PVR). There is therefore, a progressive 
transition to a decompensated RVD with uncoupling and overt RV failure. This interaction 
between the RV and pulmonary vasculature supports the notion of studying the RV and the 
pulmonary vasculature as an integral functional cardiopulmonary unit 51, 89.   
The RV contractility reserve is reported to be 5-fold higher than that of the LV, giving it 
a relatively longer period to adapt to the increased pulmonary vascular load before the onset of a 
decompensated RV failure 10. Spruijt et al, tested this concept of reactive contractility increase in 
patients with IPAH and showed that they already had maximally increased RV contractility at 
rest, indicating an early onset of RVD 26. Consequently, assessing indices of RV contractility 
using PV loop analysis can provide insights into the onset RVD 51, 89, 90. We therefore, sought to 
employ RHC and PV loop analysis to evaluate the RV adaptation to increased pulmonary 
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pressures associated with FLI, and assess their response to hMSC exosome treatment. We 
hypothesized that hMSCs exosomes exert their beneficial effects in part, by modulating RV 
contractility.   
3.2 MATERIALS AND METHODS 
3.2.1 Design 
This study was an in vivo experimental design aimed at recapitulating human IPF in a mouse 
model of bleomycin-induced fibrotic lung injury. Pressure-volume (P-V) loop analyses were 
performed to assess the RV function after fibrotic lung injury followed by transplantation of 
exogenous hMSCs and their derived exosomes. All animal protocols were approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee (IACAUC). 
3.2.2 Isolation and Characterization of human MSC-derived exosomes 
Clinical grade bone marrow-derived hMSCs were obtained from  the NHLBI-sponsored 
Production Assistance for Cellular Therapies (PACT) program based at the University of 
Minnesota, MN 91. Exosomes (EXO-20) were isolated from these hMSCs as previously 
described by our group and others 45, 92. Briefly, hMSCs were cultured and expanded in T175 
cm2 flasks (ThermoFisher Scientific) to 80% confluency for the first passage, and then separated 
into three T175 flasks for the second passage to 80% confluency. Thereafter, the cells from three 
T175 flasks (on average 20*106 cells) were washed, detached, and seeded in a triple-layer flask 
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(ThermoFisher Scientific) with 400ml of exosome-depleted maintenance media. Every other 48 
hours, the conditioned media was collected and passed through multiple differential 
centrifugation (300g/10mins, 2000g/20mins, 10,000g /hour) followed by an ultracentrifugation 
step on a sucrose cushion (100,000g/2hours) 93.This process was repeated to have 8-10 
collections/isolates of exosomes from the same parent hMSC that was pooled for protein assay 
using a Micro BCATMProtein assay kit (ThermoFisher Scientific) and  their  size 
distribution/concentrations were evaluated by Nanosight Tracking Analysis on a NanoSight 
LM10 (Malvern, Westborough, MA). 
3.2.3 Mouse model of bleomycin-induced fibrotic lung injury 
Ten-12-weeks old female C57BL/6N mice (Charles River Laboratories, Wilmington, MA) were 
randomly assigned, to four experimental groups/conditions (Controls, bleomycin (BLM) only, 
BLM+hMSC, BLM+exosome]. Ear tag numbers were used to generate random numbers that 
were randomly assigned to the four experimental conditions. To induce fibrotic lung injury, 
twelve doses of 20U/kg of bleomycin (APP Pharmaceuticals, Schaumburg, IL) were 
administered subcutaneously in 100ul of normal saline every other day for a total of 240U/kg 29, 
94. Following established lung injury after the sixth dose of BLM, the first dose of 500,000 
human mesenchymal stem cells (25 x 106 MSCs/kg, body weight) and exosomes (50ug/kg, body 
weight) were injected intravenously by the jugular vein in 160ul of normal saline-vehicle. The 
control mice received the same volume of vehicle. A second dose of the same amount of hMSCs 
or exosomes was given intravenously by tail vein after the twelfth injection of BLM. The mice 
were monitored and anesthetized for PV loop analysis 7 days after the last dose of BLM for a 
total exposure period of 31 days.  
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3.2.4 Animal handling and pressure-volume loop measurements 
The mice were anesthetized with intraperitoneal urethane (ethyl carbamate) solution (1 mg/g, 
body weight) and intubated with a 1.3 mm cannula. The cannula was connected to a ventilator 
that was set at a tidal volume of 225ul with 200 breaths/min. An apical stab wound was 
established with a 20G needle to insert a 1.2 F admittance pressure-volume catheter (Transonic 
Systems Inc, Ithaca, NY) into the RV (Figure 1). The admittance catheter has features to 
instantly measure pressures and simultaneously determine absolute volumes by calibrating phase 
shifts of the generated electrical fields. These phase shifts are used to subtract the contribution of 
the ventricular wall (parallel conductance) to the overall volume signal 95, 96. After setting the 
instruments, PV loop analysis were performed at steady state and following caudal vena cava 
occlusion for load-dependent and load-independent values, respectively. The right ventricular 
pressure and volume readings were captured on an ADV500/ ADVantage system (Transonic 
Systems Inc, Ithaca, NY) with an integrated LabChart software (ADInstruments Inc., Colorado 
Springs, CO) for post-data acquisition analysis. 97.  
3.2.5 Pressure-volume loop analysis 
The P-V loops used in our analysis went through a quality control process by the P-V loop data 
analyst. For each experimental condition, at least 10 consecutive cardiac cycles free of 
arrhythmias were selected and recorded for further analysis. The selection was done consistently 
across the experimental dataset with and without caudal vena cava occlusion. Standard 
hemodynamic variables (heart rate, systolic and diastolic pressures), right ventricular function 
volumetric parameters (CO, EF, SV), Ees, and Ea were recorded from the hemodynamic data 
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(Table 4). Contractility was quantified from the slopes of the ESPVR (Ees), PRSW, and the 
dP/dtmx-end diastolic volume (dP/dtmx-EDV) relationships. Finally, right ventricular-vascular 
coupling efficiency was calculated as Ees/Ea ratio 70, 96, 98. 
3.2.6 Primary and secondary outcomes 
Our primary endpoint was RV contractility that was determine from the slopes of three indices 
(ESPVR (Ees), PRSW, and dP/dtmx-EDV relationship. The secondary endpoints were right 
ventricular systolic pressure, mean pulmonary arterial pressure (mPAP), pulmonary vascular 
resistance (PVR) and the right ventricular elastance-to-pulmonary artery elastance (Ees/Ea) ratio. 
3.2.7 Sample size and power calculations 
The level of significance (α) and power (1-β) were set a priori at 0.05 and 0.8, respectively. The 
power to detect a 0.5 change in the slope of the ESPVR (Ees) and its standard deviation (0.20), 
were obtained from the first study ever reported on the RV function in mice using P-V loop 
analysis 97. A G*Power statistical package 99 with its integrated ANOVA F-test, was used to 
determine a minimal sample size of 55 mice needed to detect a 0.5 change in the end-systolic 
elastance between the experimental conditions.  
3.2.8 Statistical analysis 
The data were summarized as the mean±SEM or median where appropriate, and dot plots to 
show the raw data. An ANOVA or a Kruskal–Wallis tests were used for three or more group 
 38 
comparisons. Where necessary, a Tukey-Kramer or Dunn post-hoc multiple comparison tests 
were performed when the overall F-test was significant. A p-value of <0.05 was the statistically 
significant threshold and STATA statistical software (StataCorp, College Station, TX, Version 
15.0) was used for all analyses. The non-parametric Kruskal-Wallis test was used when the 
ANOVA assumptions were not met. 
3.3 RESULTS. 
Our findings showed that the average body weight of the BLM injured group was significantly 
lower when compared to controls (p <0.05;18.0 ± 0.33 vs 22.2± 0.40, g). The weight loss was 
significantly increased by administering human MSCs (18.0 ± 0.33 vs 21.5 ± 0.60, g) and EXO-
20 (18.0 ± 0.33 vs 20.1 ± 0.49, g). This indicated a beneficial effect on weight gain following the 
injection of both hMSCs and exosomes (Table 4).  
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Figure 5 Dot plots: Indices of RV contractility (A & B), afterload (C) and coupling efficiency (D). 
 
3.3.1 Cardiopulmonary hemodynamic data.  
Load-dependent measures of contractility (EF, SV) were slightly lowered by BLM injury (47 vs 
48, %; 21.6± 0.88 vs 23.8±1.57, ul), respectively. Moreover, BLM injury significantly reduced 
the CO (10.5±0.43 vs 12.2±0.98, ml/min), which is another index of load-dependent 
contractility, from baseline-controls (Figure 5). This reduction was significantly increased by 
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injecting hMSCs (18.8±2.69 vs 10.5±0.43, ml/min) and exosomes (17.2±2.59 vs 10.5±0.43, 
ml/min).  
 
 
Table 4 Hemodynamic characteristics and indices of pressure-volume relationships 
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3.3.2 Afterload 
Indices assessing RV afterload (mPAP, RVSP, PVR) showed a wide range in their response to 
an intervention with hMSCs and exosomes. As shown in Table 4, the mean pulmonary arterial 
pressure (mPAP) was significantly increased in the BLM injury group when compared with 
controls (20.0±0.45 vs 16.1±0.43, mmHg). The BLM-induced increase in pulmonary pressure 
was attenuated but insignificantly after administering hMSCs and exosomes. The same trend was 
observed in the RV systolic pressure (RVSP) when comparing the BLM injury group with 
controls (29.8±0.69 vs 23.9±0.66, mmHg) and following injections of hMSCs and exosomes 
(Table 4). However, the pulmonary vascular resistance (PVR), another metric of afterload, was 
significantly increased by BLM injury when compared with controls (1.7±0.08 vs 1.2±0.07, 
wood unit). The injection of hMSCs and exosomes significantly reduced the BLM-induced 
increase in afterload (1.7±0.08 vs 1.1±0.20; 1.7±0.08 vs 1.2±0.41, wood), respectively. 
Collectively, both hMSCs and exosomes had beneficial, but mostly nonsignificant, effects in 
reducing the RV afterload. This data indicates that the beneficial effects of hMSCs and exosomes 
on RV afterload in this study might have been insufficient because of its dose-dependent effect.  
3.3.3 Contractility 
All three load-independent measures of contractility, Ees, PRSW, and dP/dt-EDV increased but 
not significantly after BLM injury compared with controls by 24%, 17%, and 28%, respectively. 
However, only the increase in contractility comparing dP/dt_EDV in the BLM injury group with 
controls was statistically significant (45.5±2.52 vs 32.8±2.87, mmHg.s-1. ul-1). There was a 
marked but nonsignificant reduction in contractility following treatment with both hMSCs and 
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exosomes (Table 4). Similarly, as noted above with afterload, this suggested a potential dose-
dependent effect of hMSCs and exosomes on RV contractility. The P-V loops in Figure 6 
illustrate the changes in contractility under the different experimental conditions. The greater the 
steepness of the slope of the end-systolic pressure to volume relationship (ESPVR), the stronger 
the contractility. There is a stronger and possibly complete RV contraction when comparing the 
BLM group to controls (Figure 6). The contractility in the hMSC group was reversed towards 
that of the controls, indicating an improvement in RV contractile reserve.   
 
 
 
Figure 6 Slopes of the end-systolic pressure-volume relationships 
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3.3.4 Coupling efficiency 
The coupling efficiency, which is the optimal RV work to pump blood through the pulmonary 
artery with minimal energy consumption, is assessed by the Ees/Ea ratio. It showed a 
nonsignificant decrease comparing BLM injury to control groups (0.51 vs 0.53). There was a 
minor beneficial effect from injury after administering hMSCs and exosomes (Table 4 & Figure 
5). Overall, the coupling efficiency was determined to be suboptimal since all the ratios were 
above 0.5. This indicated that the coupling efficiency of the RV supply to the pulmonary 
vasculature demands was maintained despite the BLM-induced increase in the RV afterload. 
3.4 DISCUSSIONS 
The results showed that the RV afterload was significantly increased and accompanied by an 
adaptive increase in RV contractility from baseline. Furthermore, the intravenous injections of 
hMSCs and exosomes after an established fibrotic lung injury, showed beneficial effects on right 
ventricular contractility and afterload. Some of the insignificant beneficial effects could have 
been in part, due to the dose-dependent mode of action of both hMSCs and exosomes.  
Afterload. We found that BLM injury significantly increased RV afterload indices 
(RVSP, mPAP, PVR) that were reversed by hMSCs treatment. Similarly, lower improvements 
were observed after treatment with exosomes (Table 4). Consistent with our results, Tabima D. 
et al 97 using admittance-derived PV loop analysis, also found a significant (67.5%) increase in 
RVSP from controls following hypoxia-induced pulmonary hypertension (45±17 vs 27±3, 
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mmHg) 97. Evaluating sixty-six patients with diffuse parenchymal lung disease, Corte T et al 
found an elevated PVR (≥ 6.23 WU) as the strongest hemodynamic predictor of mortality, but 
RVSP and mPAP were not predictive of mortality 81. Even though these reports showed mixed 
findings relating RVSP and mPAP to outcomes, they all provide support for PVR as a strong 
predictor of mortality. 
Contractility. The RV supply (contractility) of blood flow assessed by a load-independent 
index of contractility (dP/dtmax.-EDV), was significantly higher among the BLM injury group 
when compared with controls. An adaptive increase in contractility has been reported as an early 
sign of RVSD 90. Recently, Guihaire et al and others, showed that an increased pulmonary 
hypertension was associated with a reduction in contractile reserve during exercise 26, 100, 101. 
These authors argue that subjects with PH already have maximally increased RV contractility at 
rest that could not adapt to the increased afterload during exercise. In our bleomycin model of 
fibrotic lung injury (FLI), we found a 28% increase in RV contractility (an early sign of adaptive 
RVSD), using the slope of the maximum pressure derivative to the end diastolic volume 
(dP/dtmax-EDV). This increase in contractility was attenuated by administering hMSCs and 
exosomes (Table 4). The increase in RV contractility as an early sign of RVD has been reported 
by other investigators in human subjects and animal models 26, 101. Tabima D. and colleagues, in 
a mouse model of hypoxia-induced pulmonary hypertension, found a 110% increase in 
contractility based on evaluating the dP/dtmax-EDV relationship 97. Yerebakan C. et al studying 
the RV adaptation to increased pressure overload in sheep, found a significant increase in RV 
contractility based on an increase in the maximal slope of systolic pressure increment (dP/dtmx, 
p=0.002)101.  Most recently, Spruijt et al evaluating patients with precapillary PH, determined 
that failure to compensate for the further increases in pulmonary pressure during exercise, led to 
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a poor RV contractility matching the increased RV pressure overload 26. Collectively, therefore, 
an increase in RV contractility is an early indicator of RVD. Of the indices routinely used to 
assess RV contractility (Ees, PRSW, dP/dtmax-EDV), dP/dtmax-EDV was reported as the most 
reliable load-independent measure of contractility 97 and thus, confirming our use of this index as 
a measure of RV contractility. 
Coupling efficiency. The ratio of ventricular elastance (Ees) to the effective arterial 
elastance (Ea), provides a quantitative assessment of how the RV ventricular systolic function 
adapts to increased RV afterload 22. In mice, a ratio greater than 0.5 shows that the ventricle is 
operating at optimal efficiency with minimal energy spent to overcome the RV afterload 102. Our 
findings showed an Ees/Ea ratio that was borderline greater than 0.5 in all experimental 
conditions. This suggest a preserved, suboptimal ventricular-arterial coupling efficiency and a 
state of compensated RVD. Wauthy et al, studying RV contractile function in different large 
animal species (dogs, goats, pigs), also reported a preserved optimal ventricular-arterial coupling 
despite an increase in pulmonary hypertension 27. Put together, a preserved ventricular to 
pulmonary vascular coupling does not preclude an underlying RVD because is reflection of an 
interaction between RV contractility (Ees) and RV afterload (Ea). 
Notwithstanding the potential beneficial effects of hMSC and their exosomes in fibrotic 
lung injury and cardiac remodeling, the contributions of resident tissue stem cells in the heart and 
lungs is still not fully understood 37, 103.It was recently reported that resident tissue MSCs may 
differentiate in a hierarchical fashion with increased specificity in tissue repair function 
according to the paracrine and autocrine cues in their microenvironment 104. A potential 
paracrine cue may come from the secreted exosomes of ex vivo transplanted hMSCs. Allogeneic 
hMSCs have been shown to ameliorate their bioenergetic properties by extruding mitochondria 
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to recipient cells through secreted extracellular vesicles 45, 105. Therefore, mitochondrial transfer 
between transplanted hMSC exosomes and resident cardiac and lung stem cells will be a 
potential mechanism through which stem cells (endogenous and exogenous) interact to repair 
damaged tissues. 
Limitations. In inexperienced hands, measuring cardiac volumes using an admittance 
catheter in mice is always  challenging due to the crescentic trapezoid shape of the right ventricle 
96. We employed the expertise of the personnel at the Vascular Medicine Institute at the 
University of Pittsburgh who have gained much experience in conducting PV loop analysis in 
mice over the years. The volumes from our P-V loop data were relatively higher than those 
previously reported in mice 97. This may have reduced the absolute values of some of the 
variables indexed by volume such as the dP/dtmax.-EDV, thus hindering effective comparisons 
with other studies. Despite this limitation, the trend and directions of our findings were 
comparable to previously published data. We did not use a dose escalation protocol for hMSCs 
and exosomes, which could have allowed us to draw clear conclusions on their dose-dependent 
effects.  
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4.0  A DESCCRIPTIVE PROTEOMIC ANALYSIS OF HMSC EXOSOMES: 
THERAPEUTIC IMPLICATIONS IN FIBROTIC LUNG DISEASES  
4.1 INTRODUCTION 
Human bone marrow-derived mesenchymal stem cells (hMSCs), which is the most studied of all 
hMSCs, hold promise as therapy for complex diseases such as fibrotic lung diseases 106, 107. 
There has been a shift in paradigm, from the previous postulate that transplanted MSCs engraft 
and differentiation into damaged resident cells to one based on MSCs releasing paracrine 
effectors52. The hMSC secreted paracrine factors (secretome) comprise soluble factors and 
insoluble extracellular vesicles (EVs)33. These EVs include nanosize exosomes (30-100 nm in 
diameter), which originate from the endosomal compartment, and microvesicles (MVs, 0.1 to 
1µm in diameter), which are formed from plasma membrane blebs 108. While MVs can be 
isolated from biofluids and cell culture supernatant at low centrifugation (10,000-12,000g), the 
isolation of exosomes requires ultracentrifugation at 100,000-120,000g 109. 
Human MSC exosomes have been demonstrated to protect mice from myocardial 
infarction, pulmonary arterial hypertension and bleomycin induced fibrotic lung disease 56, 110. 
Also, their use in clinical trials have been reported in other countries 39. Despite the excitement 
generated in the potential of hMSC exosomes to treat fibrotic lung diseases, however, the 
components of the hMSC exosome proteome that is responsible for their therapeutic effect are 
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still not well characterized. Identifying the unique protein components that confer the therapeutic 
effects of hMSCs will go a long way in filling the current knowledge gap in markers of hMSC 
therapeutic efficacy/potency. Biomarkers of MSC potency or efficacy are key to translating 
hMSC exosomes into reproducible and measurable clinical applications. Lee RH. and colleagues 
recently reported the expression of TSG6 as a biomarker to predict the efficacy of BM-MSCs 
prepared by standardized protocols. Surprisingly, they found that only one-third of their 
preparations expressing high levels of TSG6 produced beneficial effects in a mouse model of 
induced inflammatory cornea disease 40. Other investigators have suggested Twist 1 as predictive 
biomarkers of the proliferative potential of hMSCs. They correlated high proliferative capacity 
with therapeutic potency based on in vitro assays 111. Put together, adequate candidate 
biomarkers that are predictive of hMSC efficacy need to be identified and validated, in vivo in 
animal models. The assumption is that efficacious hMSCs will also release efficacious 
exosomes, but several studies have shown that exosomes are differentially enriched in miRs and 
mRNAs and potentially their protein load when compared with their parent cells 49. Therefore, 
protein components that can be identified and validated as adequate biomarkers directly from 
exosomes will be better predictors of hMSC efficacy. 
Recently, we showed that hMSCs exert their beneficial actions in part, by shuttling their 
extravesicular cargo (microRNA, proteins) to macrophages and, as a result, changed their 
immunomodulatory phenotype 45. This study and others 53 suggest a potential cross-talk between 
hMSC exosomes and target cells such as endothelial, cardiomyocytes, and lung epithelial cells 
for tissue repair following different types of injury. In recent years, the role of oxidative stress in 
tissue injury, including fibrotic lung disease, has caught the attention of several investigators 57, 
61. Most reports have shown an increased expression of NADPH oxidase (NOX) and 
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mitochondria as the main sources of ROS production that led to the development of pulmonary 
and RV remodeling 59, 60. These data suggest that excessive ROS production (oxidative stress) is 
deleterious to the normal interaction (coupling) of the RV to the pulmonary artery. Also, 
increased ROS generation has been shown to positively correlate with high levels of misfolded 
or damaged proteins  64, 65. If allowed to accumulate and not degraded by homeostatic pathways, 
these misfolded proteins will invariably induce the injury observed in cardiopulmonary 
remodeling 59. A key pathway in protein homeostasis is the ubiquitin/proteasome pathway 66, 112. 
Proteasomes are an essential group of hydrolase proteolytic enzymes that have also been 
identified in exosomes 66. According to these authors, proteasomes played a key role in clearing 
misfolded proteins to mitigate ischemia/ reperfusion (I/R) injury. Put together, these data indicate 
a pivotal role of proteasomes in the clearance of damaged proteins within cells. Their 
intracellular proteolytic effects may be augmented by the extracellular proteolytic effects of 
matrix metalloproteinases (MMPs) within the ECM. Specifically, the gelatinases (MMP2 and 
MMP9) are MMPs that play a critical role in ECM protein turnover 67. Therefore, a combined 
antioxidant and proteolytic turnover of damaged proteins may in part, explain the pleiotropic 
beneficial paracrine effects of hMSC-based therapies reported in complex fibrotic lung diseases 
such as IPF. To facilitate the translation of hMSc exosomes from preclinical to clinical trials, the 
protein components that confer their therapeutic potential must initially be identified using 
modalities that can reliably analyze their complex protein cargo (proteomics) within a short 
timeframe. This has been made possible since the mid-90s with the development of high-
performance liquid chromatography (HPLC) coupled to mass spectrometry (MS). The basic 
principles in proteomic analysis by MS initially involve loading microliters of a trypsin digested 
protein onto HPLC C (carbon)-18 columns. Analytes in solution are separated based on their 
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hydrophobicity and the eluted peptides are then transferred onto an electrospray ionization (ESI) 
device that is linked to a MS 113. The peptides are ionized and fragmented to generate tandem 
mass spectrometry (MS/MS) spectra that are searched against curated protein databases for 
protein identification. Proteomic analysis of various complex protein cargos generates huge high-
throughput data that need bioinformatic expertise and software for their analysis and further 
classification.  
One of the first publications on the proteome of the hMSC exosome was from Lai R. and 
colleagues in the Lim S. laboratory in Singapore. They used proteomic analysis to demonstrate 
that the predominant component of the hMSC exosome proteome was the 20S proteasome. The 
20S proteasome constitutes the catalytic core of the 26S proteasome that has been shown to have 
critical physiological and pathological implications in many diseases, including myocardial 
infarction and fibrotic lung diseases 65. Furthermore, Lai R. et al showed that the presence of 20S 
proteasome correlated with a significant reduction in extracellular oligomerized or folded 
proteins, thereby, prompting these investigators to postulate that 20S proteasome may synergize 
with other components of the hMSC exosome proteome to ameliorate tissue injury 66. Following 
this article, a proteomic analysis was conducted on hMSC-derived MVs to investigate their 
therapeutic cargo by Kim H. et al. These authors reported that the proteome of hMSC MVs was 
enriched in cell surface receptors, cell adhesion and signaling molecules that may be associated 
with their beneficiary effects 114. Put together, the findings of these early proteomic analysis of 
the hMSC exosome proteome, support the notion that hMSCs mediate their paracrine effects via 
exosomes that carry proteins with cell signaling and proteolytic properties. Most recently, 
Anderson J. et al, conducted a quantitative proteomic analysis of BM-MSC exosomes that 
revealed they possess modulatory properties in angiogenesis. These investigators further 
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demonstrated that the proteome of hMSC exosomes cultured under reduced oxygen, peripheral 
arterial disease-like, conditions (serum starved with a 1% oxygen tension) contained an enriched 
profile of angiogenic signaling proteins that induced angiogenesis via the nuclear factor kappa-
light chain enhancer of activated B-cells (NFkB) pathway 115. Similarly, Haraszti RA and 
colleagues in their report on a comprehensive proteomic analysis of EVs from different cell 
sources, including BM-MSC, found that the protein profiles of exosomes were more different 
from their cell of origin than from those of MVs. In addition, the exosome protein cargo was 
enriched in extracellular matrix and immune response proteins, whereas that of MVs was 
enriched in endoplasmic reticulum, proteasome and mitochondrial proteins. These investigators 
concluded that MVs and exosomes have different protein content despite the overlap in their size 
range 116. To address the lack of markers for EV isolation and analysis, Kowal J. et al, conducted 
a quantitative proteomic analysis on four different fractions of EVs isolated from dendritic cells. 
Similarly, the findings by Haraszti et al, 2016, they concluded that mitochondria and 
proteasomes where mostly found in the 10,000 centrifugated pellet consistent with MVs, while 
extracellular matrix were specifically present in the 100,000 ultra-centrifugated pellet that was 
consistent with exosomes 117, 118. These recent proteomic analysis reports highlight the fact that 
the protein content of both types of EVs (MVs and exosomes) may confer specific aspects of the 
ameliorating effects of hMSC EVs. We postulate that this is possibly through the paracrine 
effects of unique protein candidates acting in synergistically with other protein components 
through multiple pathways.  One of the ways to test this hypothesis is through proteomic 
pathway analysis.  
Pathway analysis following proteomic analysis are conducted to have a better 
understanding of the potential intracellular pathways associated with protein components of the 
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hMSC exosome proteome that may impart their beneficial effects. Many of these proteins, 
specifically enzymatic proteins that catalyze these biochemical reactions have been curated in 
pathway databases. One of the most widely used pathway databases is the Kyoto Encyclopedia 
of Genes and Genomes (KEGG). KEGG is a collection of knowledgebase databases that links 
large-scale molecular datasets, including proteomic analysis, to high-level cellular and biological 
systemic functions 119. According to Kanehisa and colleagues, the KEGG PATHWAY database 
is key to the KEGG resource, containing annotated proteins classified with KEGG Annotation 
Analysis into sections, such as metabolism and cellular processes 120. Therefore, this pathway 
database will be crucial in identifying key enzymatic proteins and their biochemical pathways 
following proteomic analysis of the hMSC exosome proteome.  
Comprehensive (quantitative) proteomic analysis allows for absolute protein 
quantification that would be essential to compare the proteome of hMSC exosomes from 
different donors, however, previous knowledge on the protein composition (predefined peptides) 
is required for such an approach 121. Moreover, there is limited data in the literature on the 
components of hMSC exosome proteome. Consequently, there is the need for of an initial 
descriptive proteomics, to identify key protein components that could be relevant in a future 
comprehensive comparative proteomic analysis. We therefore, sought to initially investigate the 
hMSC exosome proteome by qualitative proteomic analysis for potential protein components. 
We hypothesized that hMSC exosome proteome will contain protein components with 
proteolytic and antioxidative activities.  
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4.2 MATERIALS AND METHODS 
4.2.1 Design 
This was a descriptive proteomic analysis to identify and categorize the protein components of 
hMSC exosome proteome. 
4.2.2 Source of human MSCs and exosome isolation 
Well characterized BM-MSCs were obtained from the NHLBI-sponsored Production Assistance 
for Cellular Therapies (PACT) program based at the University of Minnesota, MN 91, 122. 
Exosomes were isolated from these hMSCs as we and others have previously described 45, 92. 
Briefly, hMSCs were cultured and expanded in DMEM media containing 15% FBS, 2% human 
serum and 2mM Glutamax in a T175 flask (ThermoFisher) to 80% confluency for the first and 
second passages. After the second passage, hMSCs were plated in multilayered tissue culture 
flasks (Millipore Sigma) in 400ml of maintenance media with exosome-depleted FBS 
(ThermoFisher) for exosome isolation. The 48 hours conditioned media from a total of 20 X106 
hMSCs was collected and subjected to multiple differential ultracentrifugation steps as 
previously described 45, 93. 
4.2.3 Pooling and purification of exosomes  
The 8-10 isolates of crude exosomes from a single donor hMSCs, were pooled and purified over 
a 30% sucrose cushion in Tris/deuterium at 100,000g/ 2hrs as previously described by our group 
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and others 45, 93. The pellets of the pooled samples were resuspended in 100ul of PBS and 
aliquots were taken for proteomic analysis, protein assay using a Micro BCATMProtein assay kit 
(ThermoFisher), and Nanosight Tracking Analysis (NTA) with a NanoSight LM10 for size 
distribution profile and concentrations (Malvern, Westborough, MA). The quality of the 
exosomes used for this proteomic analysis was determined to be good (427x 106 P/ug) based on 
the ratio of particle count (particles/ml by NTA) to protein concentration (ug/ml, micro BCR 
protein assay) of ≥300 x 106 P/ug according to Webber and Clayton 93(Figure 7). 
 
 
Figure 7 .  hMSC exosome size distribution profile; mean size (90nm) 
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4.2.4 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and in-gel digestion 
Protein extracts (100ug) from the pooled biological replicates of hMSCs exosomes were 
separated with a 1D sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) on 
a 10% BoltTM-Tris Plus gel (ThermoFisher) under denaturing conditions in MOPS (3-N-
Morpholinopropane Sulfonic acid) running buffer. Following staining in SimplyBlueTM 
SafeStain (ThermoFisher), eight- 1mm cubic protein bands were cut per lane and placed in clean 
1.5 ml Eppendorf tubes containing 100ul of double deionized H20. The samples were then 
transmitted to the Biomedical Mass Spectrometry Center at the University of Pittsburgh for in-
gel tryptic digestion followed by proteomic analysis. 
4.2.5 Liquid chromatography tandem mass spectrometry 
 The in-gel tryptic digestion produced peptide mixtures that were analyzed by a reverse phase 
nano-HPLC coupled to an LTQ XL linear ion trap mass spectrometer (ThermoFisher) as 
described previously by the Yates group at the University of Pittsburgh Biomedical Mass 
Spectrometry Center 123 who performed the analysis. Briefly, full scan high resolution mass 
spectra were recorded at a rate of 1 spectrum/ sec. using a 300 Da to 2000 Da scan range. One 
microliter of digested sample was loaded with an autosampler onto a capillary sample trap 
column (100μm inner diameter (i.d) x 2.5cm) and desalted on line for 3 min at 3μL/min with 
solvent A [100% HPLC grade water, 0.1 Macetic acid]. After 4 minutes, the flow rate was 
reduced to 1 μl/min and peptides were eluted into an in-house packed spray tip column (100 μm 
i.d, 190μm outer diameter (o.d) × 8 cm). Thereafter, peptides were analyzed on an LTQ XL 
linear ion trap using a 75 min gradient run. The gradient was delivered by an Agilent 1100 
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capillary pump with four distinct sections; 90% Solvent B, followed by equilibration 100% A at 
1μL/min from 60 to 75 min. 
4.2.6 Identification of peptides and proteins 
This was performed at the University of Pittsburgh Biomedical MS Center by very 
knowledgeable and skilled personnel in proteomic analysis as reported previously 123. Briefly, 
the liquid chromatography tandem mass spectrometry (LC-MS/MS) spectra were acquired by 
data-dependent acquisition using 2 m/z isolation width. Each MS/MS product ion spectra were 
linked to a corresponding precursor ion feature, and DTA files were created for all precursor-
linked MS/MS spectra from all raw data files. The DTA files were searched against Peptide 
Atlas database using the SEQUEST (Thermo Finnigan) search algorithms. Search parameters 
specified a tryptic enzyme cleavage at lysine or arginine, except when followed by a proline 
residue. A maximum of three missed cleavages were allowed within each peptide. Additional 
parameters included a precursor ion tolerance of ±80 parts per million (ppm), fragment ion 
tolerance of 0.5 Da, fixed alkylation of cysteine (+57.021 Da), variable oxidation of methionine 
(+15.9950 Da) and variable phosphorylation of serine, threonine, and tyrosine (+79.9660 Da). 
All other parameters were set to default SEQUEST values. Search result output files were 
submitted to a Prophets-based algorithm in Elucidator (Peptide Tellers) or Scaffold (Proteome 
Software) to create a statistical model for assigning cross-correlation values to peptide 
identifications. Filter settings were set to a predicted false discovery error rate of 0.005.  
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4.2.7 The Kyoto Encyclopedia of Genes and Genomes pathway analysis 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) enzyme database in the chemical 
information category was used to determine the protein enzyme composition of hMSCs and the 
chemical reactions they catalyze. KEEG is a collection of knowledgebase databases that link 
molecular datasets from high-throughput experiments, including proteomic analysis to high-level 
cellular and biological systemic functions 119. According to these authors, the KEGG 
PATHWAY database is the core of the KEGG resource with annotated proteins classified into 
sections such as metabolism and cellular processes. The quality of databases is key to their utility 
as reference database. Since 2015, an addendum category was included in the KEEG database 
making it possible to collect protein sequence data from published literature as oppose to just 
relying on imported genome sequence from RefSeq. The information derived from chemical 
information category, facilitates the conversion of enzyme sets to a KEGG number set, enabling 
interpretation of high level biological processes. 
4.2.8 Statistical analysis  
Statistical analysis of large-scale proteomic data involves simultaneous, multiple hypotheses 
testing that is associated with an increased number of false positives. Multiple testing correction 
procedures are therefore required to address this issue. Estimating and controlling for the false 
discovery rate (FDR) was used as a multiple testing correction method 121.  
The FDR method was first proposed by Benjamini and Hochberg 124 to correct for 
multiple testing errors. In this procedure, the individual uncorrected p-values were ranked from 
smallest to largest. The smallest or topmost p-value was ranked first, i=1, the next that follows is 
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second, i=2, etc. Afterwards, each individual p-value was compared to its calculated Benjamini-
Hochberg (BH) critical value:(i/m) Q; where ‘i’ is the rank, ‘m’ is the total number of multiple 
tests, and Q is the chosen FDR, in this case 0.005. The first largest p-value on the list that was 
less than the BH critical value was considered significant and all other p-values smaller than the 
largest p-value were also reported as significant. In proteomic analysis, the FDR is controlled for 
during the peptide identification and protein assembly phases. 
At the peptide identification phase, the SEQUEST search algorithm identifies each 
tandem mass spectrum that represents an individual peptide. The SEQUEST program then uses 
this information to search against a knowledgebase protein database for candidate peptide 
sequences that match the observed spectrum. These theoretical spectra, from the database, were 
matched to the observed mass spectrum by cross-correlation assessments, which is a measure of 
the similarity between two spectra. This process involved multiple hypotheses testing to generate 
a ranked list of peptide-spectra matches (PSMs) based on the cross-correlation scores with their 
corresponding uncorrected p-values. The p-value for a given target PSM cross-correlation score 
(s), was determined by calculating the percentage of decoy (from the decoy database) PSMs that 
received the same score or higher (≥s). The null model here is the lack of a match between target 
PSM and decoy PSM scores 125. 
At the protein assembly phase of the proteomic analysis, the tandem MS spectra are 
matched to the amino acid sequence of specific peptides whose patterns are used to determine 
their parent proteins. Annotated knowledgebase programs such as the KEGG database are then 
used to elicit their role in biological processes. The KEEGG pathway enrichment analysis 
identifies proteins from the input raw data lists that are enriched in a pathway associated with a 
phenotype. We tested the sample-level 126 null hypothesis that gene products (proteins) of a 
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pathway (first dataset) are no more associated to a phenotype than non-pathway (second dataset) 
proteins. A hypergeometric test was used to test  this hypothesis with their corresponding 
uncorrected p-values 127. The Benjamini-Hochberg procedure was then applied to adjusts these 
uncorrected p-values to control for FDRs as described above. 
4.3 RESULTS 
We identified a total of 845 proteins in our hMSC exosome sample. Using the KEGG pathway 
program, the identified proteins were mapped to specific biological pathways (Table 5). Proteins 
associated with arrhythmogenic RV cardiomyocytes, ECM receptor interactions and proteasomes 
made up the 5-topmost all protein groups. Out of these, 166 were enzymatic proteins of which 
proteasomes, glycolysis/gluconeogenesis, and pentose phosphate pathway proteins were among 
the 4-topmost biological processes. 
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Table 5 A. All 845 identified proteins; B. Main biological processes of the 166 identified enzymes 
 
 
The major enzyme groups were hydrolases (48.2%) followed by transferases (21.1%) and 
oxidoreductases (16.3%) (Table 6). 
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Table 6 Distribution of enzymes by class in hMSC exosome proteome 
 
 
Enzymes are known to regulate many biological processes such as cellular bioenergetics and 
extracellular matrix turnover. In assessing the enzymatic activities (Figure 8), 57% of the 
hydrolases acted on peptide bonds (proteinases) and 15% on acid anhydride bonds (ATPases). 
Most of the hydrolases comprised proteasomes (PSMA, PSMB), extracellular matrix 
metalloproteinases (MMP2, MMP14) and ATPase (ATP2B4) that have been reported to be 
associated with ECM turnover and cardiac remodeling 67. This suggest that hMSC exosome carry 
enzymatic proteins that could be transferred to target cells, including cardiopulmonary cells to 
change their phenotype for tissue repair. 
Of the transferases, 29% were phosphotransferases, 26% glycosyltransferases, and 18% 
acyltransferases. Moreover, key enzymes of the glycolytic pathway such as pyruvate kinase 
(PKM1) and phosphoglycerate kinase (PGK1) were also identified. This indicates that hMSC 
exosomes are vectors of enzymes that could be internalized by target cells to modulate their 
bioenergetics.  
With regards to the oxidoreductases, 26% were CH-OH donors such as malate dehydrogenase 
(MDH1), an important NADP generator, 19% peroxide acceptors, and almost half (40%) were 
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grouped as miscellaneous, which included lysyl oxidase (LOX) a crucial enzyme involved in 
cross-liking collagen fibrils to stabilize the ECM. Importantly, a peroxide acceptor, glutathione 
peroxidase 3 (GPX3) was identified in our hMSC exosome sample. Glutathione peroxidase 3 is 
important in protecting cells against oxidative stress damage. 
 
 
Figure 8 Distribution of enzymes by class in hMSC exosome proteome with their protein symbols 
 
Collectively, these enzymatic proteins have the potential to inhibit and scavenge 
excessive ROS generation (glutathione peroxidase and pentose phosphate pathway), regulate 
ECM turnover (proteasomes, matrix metalloproteinases, and lysyl oxidase), and modulate the 
bioenergetic phenotype of target cells through glycolysis (pyruvate kinase).   
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4.4 DISCUSSIONS  
In our descriptive proteomic analysis, we identified 845 distinct proteins and of these, 166 
(19.6%) were categorized as enzymes. Enzymes are proteins that are well known to catalyze 
biochemical reactions and have the potential to alter biological processes in cells. There is 
increasing evidence that a reasonable number of proteins in exosomes have enzymatic functions 
66.  
Our proteomic pathway analysis identified proteins that were associated with the 5-
topmost biological processes, which included arrhythmogenic RV cardiomyocytes, ECM 
receptor interactions and proteolytic proteasomes. Of the enzymatic groups identified, the 
hydrolases comprised proteasomes, extracellular matrix metalloproteinases, and ATPase that 
have implications in ECM turnover and cardiac remodeling 67. This data is consistent with 
reports by Lai R. et al, who found 857 proteins in the proteomic analysis of the hMSC exosome 
proteome and demonstrated that 20S proteasome was the 8th predominant protein component. 
Just as Lai R. et al, we found all seven alpha and beta subunits of the 20S proteasome in our 
proteomic data (Figure 3). The authors also detected an overrepresentation of all seven alpha 
(PSMA) and beta (PSMB) subunits of the 20S proteasome that confers the catalytic properties of 
the parent 26S proteasome in their proteome 66. Furthermore, they showed that the 20S 
proteasome subunit was responsible for the degradation of 90% of all intracellular oxidatively 
damaged proteins 66. The publication by Lai R. et al was specifically focused on the proteolytic 
potential of hMSC exosomes proteasomes, in the backdrop of a report that some alpha/beta 
hydrolase fold superfamily members lack enzymatic activities 128. Interestingly, proteasomes 
have been demonstrated to have extracellular proteolytic activities in an ATP/ ubiquitin-
independent manner in alveolar fluid of patients with inflammatory lung diseases 65. Proteasomes 
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may, therefore, play a pivotal role in clearing both intracellular and extracellular misfolded 
proteins 63, 65, which have widely been proven to mediate cell death and tissue dysfunction. Put 
together, hMSC exosomes carry protein mediators with proteolytic potential that could clear 
misfolded intracellular proteins and proteinaceous extracellular debris to mitigate cell death and 
inflammation. These extracellular proteolytic activities of proteasomes may be enhanced by 
traditional extracellular matrix (ECM) enzymes such as matrix metalloproteinases (MMPs). 
A major group of MMPs known to play a crucial role in ECM clearance are the 
gelatinases, MMP2 and MMP9 115, 129. In our hMSC exosome sample, we found MMP2 and its 
activator, membrane type-1 MMP (MMP14). In 2012, Kim Han-Soo and collaborators, showed 
that proteolysis was the fourth topmost biological process in the proteome of hMSC 
microvesicles 114. Other investigators working on the proteomic analysis of hMSC extracellular 
vesicles have demonstrated the enrichment of ECM pathway proteins in hMSC exosomes 116, 
117.Most recently, Anderson J. et al, conducted a quantitative proteomic analysis of human BM-
MSC exosomes and revealed their modulatory properties in angiogenesis. They further 
demonstrated that the proteome of hMSC exosomes contained an enriched profile of angiogenic 
signaling proteins that were capable of inducing angiogenesis 115. Taken together, hMSC 
exosomes contain proteasomes and angiogenic signaling molecules that are capable of mediating 
angiogenesis. These are key elements for any therapeutic agent that might be useful in mitigating 
RV and pulmonary remodeling. 
Similarly, in their report on a comprehensive proteomic analysis of EVs from different 
cell sources, including BM-MSC, Haraszti RA and colleagues found that the protein profiles of 
exosomes were more different from their parent cell than those of MVs. According to these 
investigators, the exosome protein cargo was enriched in extracellular matrix and immune 
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response proteins whereas, that of MVs were enriched in endoplasmic reticulum, mitochondrial 
proteins and proteasomes 116. Therefore, both types of EVs (MVs and exosomes) carry 
subcellular components with unique therapeutic potentials. Interestingly, Kowal J. et al, 
conducted a comparative quantitative proteomic analysis on four different fractions of EVs 
obtained from dendritic cells to evaluate potential markers for EV isolation and analysis 117. 
Surprisingly, they confirmed the findings by Haraszti et al, 2016, by demonstrating that 
mitochondria and proteasomes where mostly found in MVs, while extracellular matrix was 
specifically present in exosomes 117, 118. Collectively, these recent proteomic analyses 
demonstrate that both types of EVs carry protein components or subcellular organelles that can 
act synergistically to confer the most optimal therapeutic effects to repair damaged tissue. 
Potency in their therapeutic effects may also be augmented by acting in concert with other 
classes of enzymes such as oxidoreductases. 
The oxidoreductases malate dehydrogenase (MDH1) and glutathione peroxidase 3 
(GPX3), nicotinamide adenine dinucleotide phosphate (NADP+) and peroxide acceptors, were 
identified in our proteomic analysis. Importantly, the pentose phosphate pathway (PPP) was 
identified as one of the top four catalyzed biological processes. This indicates hMSC exosomes 
carry enzyme proteins that could modulate cellular oxidative stress. The PPP continuously 
generates reduced NADP+ (NADPH), which is an essential cofactor in antioxidant pathways 62. 
NADPH act as an electron donor to glutathione reductase in its catalytic reduction of glutathione 
(GSSG) to reduced glutathione (GSH), a crucial reaction in modulating oxidative stress. When 
more free radicals are generated than can be quenched, there is an ensuing oxidative stress that is 
deleterious to the mitochondria and the entire cell 130. Moreover, in a recent report from our 
group, we showed that hMSCs extracellular vesicles mediate the restoration of mitochondrial 
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function, a key source of cellular ROS, in targeted cells 45. This report was consistent with our 
previous publication that showed that TNF induced an increase in both phagocytic (NADPH 
oxidase-NOX) and mitochondrial ROS generation 131. Despite the dearth of data on hMSC 
exome proteome and their antioxidant potential, a recent article showed that the pentose 
phosphate pathway (PPP) was enriched in exosome isolated from ovarian cancer cell lines 132. 
These investigators asserted that PPP created a metabolic shift to glycolysis that may promote 
tumor metastasis but based on the several reported beneficial effects of hMSC exosomes in a 
wide range of diseases, we postulated that hMSC exosomes are most likely to modulate the 
antioxidant pathway through an increased generation of NADPH from the PPP. Collectively, 
these data highlight the potential role of hMSC exosomes as conveyors of antioxidant effectors. 
The reparative antioxidant potential of hMSC exosome can be enhanced synergistically by the 
presence in hMSC exosomes of proteolytic factors. Together, these data suggest that hMSC 
exosome have the potential to exert optimal pleiotropic therapeutic effects through the 
synergistic actions of various components of the hMSC exosome proteome, including 
modulating ECM turnover and oxidative stress as well as the proteolytic activities of 
proteasomes and MMPs to facilitate tissue repair and regeneration. 
Limitations. The current isolation and purification techniques are still insufficient to 
clearly distinguish between exosomes and MVs based on their physical and biochemical 
properties. Therefore, it is very likely that our hMSC exosome samples may contain some MVs. 
Despite this limitation, there is a growing number of investigators including our group, who 
postulate a complementary beneficial effect in the combined administration of exosomes and 
MVs for tissue repair.  
 67 
We performed a descriptive, qualitative proteomic analysis that inherently, lacks the 
ability to provide relative or absolute quantification of the identified proteins. Nonetheless, 
descriptive proteomic analysis is critical to identifying key protein candidates that could be 
further analyzed by a comprehensive comparative proteomic analysis. 
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5.0  CONCLUSIONS 
The analysis of the data from our first project on the IPF registry, showed that pulmonary 
hypertension (PH) and right ventricular systolic dysfunction (RVSD) are prevalent and strongly 
associated with survival in IPF.RHC assessments of the RV function in IPF is an important 
modality i to identify patients that are at risk of worse outcomes who may be considered for to 
benefit from novel treatment options in clinical trials.  
Based on the results from our second project, we concluded that hMSCs and their derived 
exosomes have the therapeutic potential to improve RV adaptive contractility. Their modulatory 
effects on the RV function within the context of fibrotic lung disease may improve outcomes, 
judging from the demonstrated strong association between RV function and survival.  
Lastly in our third project, we concluded that the proteome of hMSC exosome carry enzymatic 
proteins that can mediate the therapeutic effects of stem cell-based therapies. Importantly, that 
the synergistic actions of their antioxidative, ECM turnover and proteolytic properties is a 
potential mechanism employed to enhance their therapeutic effects in a wide range of diseases, 
including fibrotic lung diseases.  
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6.0  FUTURE DIRECTIONS 
A large Pennsylvania-statewide IPF registry study will be required to validate our cutoff value 
for RVD, which should be evaluated as an important factor in the development of a composite 
score for predicting outcomes in IPF. 
In our second aim, a dose-escalation in vivo experimental design, over a longer exposure 
period will be necessary to investigate the dose-dependent effect of the efficacy of hMSCs and 
their derived exosomes. This will allow for the assessment of the transition from adaptive, 
compensated RV dysfunction to overt, maladaptive, decompensated RV failure.  
Our descriptive proteomic analysis findings have laid the foundation for a future comprehensive 
proteomic analysis study that will focus on the key catalytic proteins that were identified. 
Furthermore, it will be important to investigate the hMSC exosome proteome from multiple 
human donors to compared differentially expressed proteins. This has the potential to guide the 
bioengineering of enriched exosomes that could convey key protein components for targeted 
tissue repair, screening for biomarkers of hMSC exosome potency, and for advancing the 
understanding hMSC exosome pathobiology.  
 70 
Appendix A 
Table 7  Meaning of acronyms and abbreviations 
Aconyms and abbreviations Full meaning
BFLI Bleomycin-induced fibrotic lung injury
FLI Fibrotic lung injury
CO Cardiac output
dP/dtmx-EDV Maximum systolic pressure derivative
dP/dtmx-EDV Maximum systolic pressure derivative to end-diastolic volume
Ea Pulmonary effective elastance
Ees End-systolic ventricular elastance
EDV End-diastolic volume
EF Ejection fraction
ESPVR End-systolic pressure volume relationship
hMSCs Human mesenchymal stem cells
MSCs Mesenchymal stem cells
mPAP Mean pulmonary arterial pressure
PV loop Pressure-Volume loop
PRSW stroke work
PVR Pulmonary vascular resistance
RVSP Right ventricular systolic pressure
RVD Right ventricular dysfunction
RVSD Right ventricular systolic dysfunction
SV Stroke volume
SVI Stroke volume index  
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